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In Brief
Single-cell analyses of colon biopsy
specimens from patients with ulcerative
colitis delineate how expression patterns
and shifting cell populations may shape
disease and drug resistance, and provide
a framework for linking GWAS risk loci
with specific cell types and functional
pathways.
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https://doi.org/10.1016/j.cell.2019.06.029SUMMARY
Genome-wide association studies (GWAS) have re-
vealed risk alleles for ulcerative colitis (UC). To un-
derstand their cell type specificities and pathways
of action, we generate an atlas of 366,650 cells
from the colon mucosa of 18 UC patients and 12
healthy individuals, revealing 51 epithelial, stromal,
and immune cell subsets, including BEST4+ entero-
cytes, microfold-like cells, and IL13RA2+IL11+ in-
flammatory fibroblasts, which we associate with
resistance to anti-TNF treatment. Inflammatory fibro-
blasts, inflammatorymonocytes, microfold-like cells,
and T cells that co-express CD8 and IL-17 expand
with disease, forming intercellular interaction hubs.
Many UC risk genes are cell type specific and co-
regulated within relatively few gene modules, sug-
gesting convergence onto limited sets of cell types
and pathways. Using this observation, we nominate
and infer functions for specific risk genes across
GWAS loci. Our work provides a framework for inter-
rogating complex human diseases and mapping risk
variants to cell types and pathways.714 Cell 178, 714–730, July 25, 2019 ª 2019 Elsevier Inc.INTRODUCTION
Tissues function through the coordinated actions of diverse
epithelial, immune, and stromal cell types. Breakdown in any
compartment can lead to disease, either because of intrinsic
cell dysfunction or the compensatory actions of other cells
attempting to restore homeostasis. This interplay can make it
difficult to nominate the causal mechanisms that underlie dis-
ease. In the specific case of the colonic mucosa, disruptions
can lead to ulcerative colitis (UC), a subtype of inflammatory
bowel disease (IBD) (Xavier and Podolsky, 2007).
Known disease risk alleles highlight key pathways in the path-
ogenesis of IBD, including innate and adaptive immunity, gut
barrier function, and pathogen sensing and response (Liu
et al., 2015; Rivas et al., 2011). However, the underlying genes
at risk loci have not been mapped to their cells and pathways
of action. Moreover, although histological analysis following
endoscopy is the current standard of care (Magro et al., 2017),
it fails to capture fine details of disease—e.g., cell proportions,
cell type-specific expression, and cell-cell interactions—and
does not distinguish between pathways associated with chronic
inflammation versus disease restitution.
Single-cell RNA sequencing (scRNA-seq) is helping to
advance our understanding of human disease by comprehen-
sively mapping the cell types and states within a tissue,
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disentangling changes in the expression of gene programs from
those in cell frequencies, and connecting them through cell-cell
interactions (Tanay and Regev, 2017). Here we apply scRNA-seq
to UC, using intestinal biopsies collected fromhealthy individuals
and UC patients to generate and query a single-cell atlas of the
healthy and diseased colon.
RESULTS
scRNA-Seq Atlas of Colon Biopsies from Healthy
Individuals and UC Patients
We generated 366,650 high-quality single-cell transcriptomes
from 68 biopsies (each 2.4 mm2) from colonoscopic examina-
tions of 18 UC patients under different treatment regimens and
12 healthy individuals (Figure 1A; STAR Methods; Table S1).
We conducted the study in two phases: 115,517 single-cell pro-
files were collected from 34 colon biopsies of 7 UC patients and
10 healthy individuals as a training set (Figure 1A; STAR
Methods; Table S1); another 251,133 were then collected from
34 biopsies of 11 UC patients and 2 healthy individuals as a
test set.
To investigate the transitions between healthy and chronically
inflamed mucosa while mitigating patient-specific variability, we
collected paired samples from each subject in a single proced-
ure. For UC patients, these were endoscopically assessed as
adjacent normal tissue (‘‘non-inflamed’’) and inflamed or ulcer-
ated tissue (‘‘inflamed’’) (Figure 1A; STARMethods). To estimate
intra-subject variation, we obtained two location-matched sam-
ples (distance of 1–2 cm) from each of the 12 healthy subjects
as well as from both non-inflamed and inflamed regions of 3 UC
patients. We then separated the ‘‘epithelial’’ (EPI) and ‘‘lamina
propria’’ (LP) fractions from each sample and performed
scRNA-seq (STAR Methods). We confirmed that expression of
an inflammation-associated gene set increased from healthy to
non-inflamed to inflamed samples (Figure 1B).
A Comprehensive Census of 51 Cell Subsets and Their
Molecular Signatures
The single-cell profiles partitioned into 51 subsets by clustering
(Figure 1C, after correction for technical and biological variation;
STAR Methods), which we annotated by known markers (Fig-
ure 1D). The subsets were robust and reproducible becauseFigure 1. Single-Cell Atlas of Colon Biopsies from Healthy Individuals
(A) Study design. See also Table S1.
(B) Confirmation of inflammation status. Shown is the mean expression of an infl
(green), and inflamed (red) biopsies (Wilcoxon test, *p = 0.05; **p = 0.01; ***p = 0
(C) Cell census. Shown is t-Stochastic Neighborhood Embedding (t-SNE) of cell
(D) Subset-specific markers. Shown is the expression of marker genes (rows) a
legend; STAR Methods).
(E) Reproducible cell subset distributions across samples (discovery and validati
derived from each healthy (blue), non-inflamed (green), or inflamed (red) sample.
(F) Epithelial differentiation. Shown is the inferred differentiation trajectory (STAR
(left) lineages.
(G–I) New colon cell subsets and their markers. Shown are fractions of expressing
marker genes (columns) across subsets (rows) (G and I) and representative image
immunofluorescence assay (IFA) of a colon tissue microarray (TMA; STAR Meth
white arrow) in healthy colon (H). Inset, 33 magnification; scale bars, 50 mm.
See also Figures S1 and S2 and Tables S1, S2, and S3.
716 Cell 178, 714–730, July 25, 2019nearly all were represented by all specimens (Figure 1E) and pro-
portionally distributed across patients (Figures S1A and S1B).
The discovery and validation cohorts were highly congruent (Fig-
ures S1B–S1D), as were replicates collected from the same and
even different individuals within the same disease state (Fig-
ure S1E; STAR Methods).
The 51 subsets include 15 epithelial subsets, ordered along
the differentiation trajectory from intestinal stem cells (ISCs) to
mature cell fates (Haber et al., 2017; Figure 1F; STAR Methods).
They also include 8 fibroblast, 4 endothelial cell, 1 glial cell, 7
myeloid cell, 4 B cell, 10 T cell (CD4+ conventional T helper cell
[Tconv], regulatory T [Treg], CD8
+, and gd), 1 innate lymphoid
cell (ILC), and 1 natural killer (NK) cell subsets (Figure 1C).
Missing cell types include submucosal enteric neurons, which
require isolation by single-nucleus RNA-seq (Habib et al.,
2016), plasmacytoid dendritic cells (DCs), and neutrophils
(Schelker et al., 2017). Each subset is supported by known and
novel markers (Figure 1D; Table S2), including transcription fac-
tors (TFs), G protein-coupled receptors (GPCRs), and cytokines
(Figures S2A–S2C; Table S3). In most cases, further sub-clusters
could not be distinguished by an additional round of clustering
(Table S2; STARMethods). Exceptions included immunoglobulin
A (IgA)+ and IgG+ plasma cells, and Treg cells co-expressing
TNFRSF4/OX40 and TNFRSF18/GITR, which may reflect acti-
vated versus resting Treg cells.
Characterization of BEST4+ Epithelial Cells and RSPO3+
Fibroblasts in the Healthy Colon
Our census revealed that enterocytes expressing BEST4 are
distinct from other epithelial cells (Parikh et al., 2019), and are en-
riched in genes related to pH sensing and electrolyte balance
(validated in situ; Figures 1G, 1H, and S1D). These include the
otopetrins 2 and 3 (OTOP2/3), proton channels that detect pH
and underlie sour taste perception (Tu et al., 2018); carbonic an-
hydrase VII (CA7), which catalyzes bicarbonate formation; and
bestrophin-4 (BEST4), which may export bicarbonate (Qu and
Hartzell, 2008). BEST4+ enterocytes comprised 1% of the ileal
epithelium from two Crohn’s disease (CD) patients (11,473 cells;
data not shown).
Multiple fibroblast subsets differ by expression of WNT/
bone morphogenetic protein (BMP) signaling genes, likely re-
flecting distinct positions along the crypt-villus axis (Powelland Ulcerative Colitis (UC) Patients
ammation signature (STAR Methods) in cells from healthy (blue), non-inflamed
.001); boxplots: 25%, 50%, and 75% quantiles; error bars: SD.
s colored by cell subset (legend; STAR Methods).
cross cell subsets (columns) ordered by cell lineage relationships (top, color
on sets). Shown are fractions of cells (y axis) in each cell subset (bars) that are
Bottom: total cell count in the subset (see also Figure S1A).
Methods) for epithelial cell subsets including absorptive (right) and secretory
cells (dot size) andmean expression level in expressing cells (dot color) of select
s of combined single-molecule fluorescence in situ hybridization (smFISH) and
ods) for BEST4+ enterocytes (left, white arrow) and RSPO3+ fibroblasts (right,
A
B
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Figure 2. Changes in Cell Composition and Differentiation in UC
(A) Cell proportion changes. Shown are significant changes in cell frequency (y axis) for non-inflamed (light blue) and inflamed (white) samples relative to healthy
(dark blue) (Dirichlet-multinomial regression, *adjusted p = 0.05, **adjusted p = 0.01, ***adjusted p = 0.001); error bars: SEM.
(B) Relative reduction in plasma cells among B cells in inflamed colon. Left: representative images of combined smFISH and IFA of plasma cells in TMA from
healthy (left) and inflamed (center) human colon; yellow arrows, plasma cell; red arrows, B cell; scale bars, 50 mm; inset, 32.5 magnification. Right: fraction of
plasma cells of total B cells (y axis) in the field of view (n = 9 biopsies per condition; *p < 0.05, t test; error bars: SEM).
(C) Expansion of IAFs in inflamed colon. Left: representative images of combined smFISH and IFA of IAFs in TMA from healthy (left) and inflamed (center) human
colon; scale bars, 50 mm. Right: number of IAFs (y axis) in the field of view (100 mm2 per image; n = 9 and n = 7 healthy and inflamed biopsies, respectively;
***p < 5 3 104, t test; error bars: SEM).
(D) Reduction in epithelial progenitors with disease. Shown is the distribution of diffusion pseudotimes (STARMethods) for absorptive (top) and secretory (bottom)
epithelial cells, colored by disease state, both significantly shifted to later pseudotimes during disease (likelihood ratio test, p = 104).
See also Figure S3.et al., 2011; Shoshkes-Carmel et al., 2018). Some are enriched
for WNT2B, WNT4, and DKK3, suggesting that they reside
near the crypt, whereas others are enriched for BMP4, BMP5,
and WNT5A/B and may reside near the villus (Figure 1I). Many
of these genes are reported markers of subepithelial telocytes,
a rare population of fibroblasts that support the epithelium
(Shoshkes-Carmel et al., 2018); however, in our data, they are
broadly distributed across all subsets (e.g., FOXL1, DKK3, and
WNT5B; Figure 1I).
One subset ofWNT2B+ fibroblasts may support the ISC niche
by expression of R-spondin-3 (validated in situ, Figures 1G–1I),
which interacts with the ISC receptor LGR5 (de Lau et al.,
2011). RSPO3+ fibroblasts express other WNT/BMP signaling
genes and several distinct chemokines (Figures 1G and 1I),
which may recruit immune cells to the ISC niche (Biton et al.,
2018). They are also enriched for genes predictive of poor prog-
nosis in colorectal cancer (CRC) (Calon et al., 2015) and maysupport tumor growth by promoting a stem-like microenviron-
ment (Figure S5A).
Remodeling of the Colon’s Cellular Composition during
Disease
The proportions of many cell subsets significantly differed in
non-inflamed or inflamed samples versus healthy controls, using
both a multivariate test accounting for compositional depen-
dencies (Figure 2A) and univariate tests (Figures S3A and S3B;
STAR Methods). These include many known changes in UC
patients, such as increases in the proportions of mast cells
(King et al., 1992), CD8+IL-17+ T cells (Tom et al., 2016), and
Treg cells (Holmén et al., 2006; Figure 2A, S3A, and S3B).
Microfold (M) cells are typically associated with lymphoid tis-
sue in the human small intestine, where they are important for
recognition of the gut microbiota (Mabbott et al., 2013). In the
colon, M-like cells were rarely found in healthy individuals butCell 178, 714–730, July 25, 2019 717
expanded 17-fold during inflammation (validated in situ; Figures
S3A and S3D). They highly express several chemokines (e.g.,
CCL20 and CCL23; Figure 1G), suggesting involvement in re-
cruiting immune cells to sites of inflammation.
Mucus layer defects (Xavier and Podolsky, 2007) were not ex-
plained by changes in expression (below), suggesting that they
may arise post-transcriptionally. Although the frequency of
goblet cells did not change, goblet cell progenitors were reduced
during inflammation, both as a discrete cell subset (Figure 2A)
and along the continuum of differentiation (Figures 1F and 2D;
STAR Methods).
Although the overall number of immune cells increased with
disease (Danese and Fiocchi, 2011), within the B cell lineage,
there was a shift from plasma to follicular (FO) cells (validated
in situ; Figures 2A and 2B). Among plasma cells, the frequencies
of IgA+ relative to IgG+ cells decreased (Figure S3C), suggesting
that inflammation is associated with immunoglobulin class
switching (Scott et al., 1986).
An Inflammation-Associated Fibroblast Subset Is
Unique to the UC Colon
Although most fibroblast subsets were present in both healthy
individuals and UC patients, a subset we termed inflammation-
associated fibroblasts (IAFs) expanded 189-fold in inflamed tis-
sue of some patients (>1% of LP cells, validated in situ; Figures
2A and 2C). IAFs are enriched for expression of many genes
associated with colitis, fibrosis, and cancer, including IL11,
IL24, and IL13RA2 (Figure 1G). Interleukin-11 (IL-11) is a regu-
lator of fibrosis in mice and potentially humans (Schafer et al.,
2017). IAFs comprise WNT2B+ and WNT5B+ subsets (Fig-
ure S3E), suggesting that they may reflect a distinct state along
the crypt-villus axis.
IAFs express markers of cancer-associated fibroblasts (CAFs)
(Figure 1G), including FAP, TWIST1, and WNT2 (Erez et al.,
2010; Kramer et al., 2017). The expression levels of IAF markers
are correlated between IAFs and 414 bulk RNA-seq CRC sam-
ples (Cancer Genome Atlas, 2012; Figure S5B; Spearman’s
r = 0.67), more than controls (r = 0.33; p < 1010; Mann-Whitney
test), suggesting an expansion of IAFs in tumors (also consistent
with increased expression of IAF markers in CRC versus con-
trols; Figure S5B).
Most Expression Changes during Disease Are Shared by
Non-Inflamed and Inflamed Tissue
To identify changes in expression associated with disease,
we modeled expression as the sum of components reflecting
cell subset, disease state (healthy, non-inflamed, or inflamed),
and technical covariates while correcting for ambient RNA
contamination (Macosko et al., 2015; Figure S1F; STAR
Methods). We distinguished between changes shared across
cell subsets in epithelial, innate, or adaptive compartments
(Figures 3A–3C and S4A–S4C, Table S4) and those unique to
each subset (Figures 3D–3F and S4D–S4F; Table S4; STAR
Methods).
Despite their endoscopic assessments, non-inflamed and in-
flamed tissue had similar differentially expressed (DE) gene sig-
natures (Figure 3G; Table S4), suggesting that the transcrip-
tional signature of UC precedes inflammation or persists after718 Cell 178, 714–730, July 25, 2019resolution. Across epithelial cells, DE genes reflect attempts
to restore homeostasis by activating innate immunity, such as
antimicrobial and antioxidant defense pathways, mucin biosyn-
thesis, and major histocompatibility complex (MHC) class II
machinery (validated in situ; Figures 3A, 3D, and 3H; Biton
et al., 2018; McDonald and Jewell, 1987). Within the stroma,
fibroblasts induced genes for inflammation, fibrosis, and
tissue repair (Gieseck et al., 2018), whereas changes in endo-
thelial cells supported tissue vascularization (Figures 3B and
3E). Among immune cells, myeloid and T cells activated co-
stimulatory and co-inhibitory genes, and B cells upregulated
genes for IgG class switching and affinity maturation (Figures
3C and 3F).
Concerted Metabolic Shifts in Epithelial Cells during
Inflammation
Comparison between non-inflamed and inflamed UC tissue (Fig-
ures S4A–S4F; Table S4) revealed several metabolic changes
in epithelial cells accompanying inflammation. For example,
changes in purine metabolism (e.g., XDH and URAD) may yield
uric acid, associated with epithelial damage (Chiaro et al.,
2017). Epithelial cells also induced the kynurenine pathway (Fig-
ure 4A), associated with disease severity (Sofia et al., 2018).
GPR35, a kynurenic acid receptor, is a putative risk gene (Huang
et al., 2017).
Mapping changes in 239 Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathways during inflammation (Figures 4B
and S5C; STAR Methods) revealed other metabolic alterations
in enterocytes, including a shift from oxidative phosphorylation
to glycolysis, induction of arginine biosynthesis enzymes (e.g.,
NOS2 and ASS1), and downregulation of enzymes for the degra-
dation of branched-chain amino acids, particularly AUH, a puta-
tive risk gene (Liu et al., 2015). Enterocytes also induced HIF1
pathways, a contributor to the glycolytic shift in monocytes (Kelly
and O’Neill, 2015). These changes may be driven by impaired
production of short-chain fatty acids by gut bacteria (den Besten
et al., 2013) because epithelial cells downregulated pathways
for b-oxidation and the metabolism of butyrate and propionate
but upregulated pathways for dietary fatty acids (e.g., a-lino-
leic acid).
Induction of a Pro-Inflammatory IL-17 Response and
Immune Checkpoints in T Cell Subsets
Among T cells, several CD4+ subsets upregulated IL17A (Fig-
ure 3C), which may reflect both a per-cell increase in IL17A
expression as well as an expansion of Th17 cells. Surprisingly,
a CD8+ subset had the strongest overall induction of IL17A
across both disease states (Figures 4C–4E). In situ analysis re-
vealed both CD4 and CD4+ cells that co-express CD8 and
IL17A (Figures 4D and 4E). Although CD8+IL-17+ T cells have
been reported (Cortez et al., 2014; Srenathan et al., 2016),
CD4+CD8+IL-17+ T cells are largely uncharacterized. These cells
also activated cytotoxic programs and genes related to Th17
pathogenicity in mice (e.g., RBPJ and IL23R; Figures 3F and
4C; Gaublomme et al., 2015), which may aggravate tissue dam-
age. Most subsets of T cells induced co-stimulatory and co-
inhibitory programs (Figure 4C), consistent with attempts to
suppress immune activation (Attanasio and Wherry, 2016).
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Figure 3. Shared Lineage-Specific and Cell-Specific Expression Changes in Non-inflamed and Inflamed Tissues
(A–G) Lineage- and cell-specific expression changes are shared by non-inflamed and inflamed versus healthy tissue.
(A–F) DE genes shared by the disease states (STARMethods) with their effect size during inflammation (discrete DE coefficient, x axis) and statistical significance
(y axis). Select genes are highlighted; all marker genes are reported in Table S2.
(A–C) Shared changes among multiple cell subsets within (A) epithelial, (B) innate (stromal and myeloid), or (C) adaptive compartments.
(D–F) Unique changes in specific cell subsets within epithelial (D), innate (E), and adaptive (F) compartments.
(G) Discrete DE coefficients estimated for non-inflamed (x axis) and inflamed (y axis) samples versus healthy samples for genes that were significantly DE in at
least one disease state (96,445 gene-by-subset coefficients, Spearman’s r = 0.71, p < 1016).
(H) Upregulation of epithelial MHC class II expression in inflamed colon. Shown are representative images of combined smFISH and IFA of epithelial cells from
TMA of healthy (left) and inflamed (right) human colon. Scale bars, 50 mm; inset, 35 magnification; dashed line, HLA-DRA+ epithelial cell.
See also Figure S4 and Table S4.TNF Expression Shifts to Treg, FO B, and CD8
+IL-17+
T Cells during Inflammation
Monoclonal anti-TNF antibodies are a breakthrough therapy for
IBD, but 30% of IBD patients do not respond, and many acquire
resistance (Rutgeerts et al., 2004). Tumor necrosis factor (TNF)
expression shifted during UC, with a prominent role for Treg cells.
Baseline expression of TNF per cell was highest in CD8+ LP and
activated CD4+Foshi T cells, but in inflamed tissue, TNF was
induced in Treg and FO B cells (validated in situ; Figures 5B
and S5D). When estimating the total amount of TNF expressed
by each cell subset (Figure 5A), Treg cells accounted for 1% ofTNF expression in healthy tissue but over 14% during inflamma-
tion (second only to activated CD4+ T cells).
IAFs and Inflammatory Monocytes Are Associated with
Resistance to Anti-TNF Therapy
One of the most enriched genes in IAFs is OSMR, a putative
risk gene (Liu et al., 2015), and the receptor for Oncostatin M
(OSM), a cytokine that predicts anti-TNF response (West et al.,
2017).OSM andOSMR are thought to be expressed by unknown
myeloid and stromal cells, respectively (West et al., 2017). OSM
was most enriched in inflammatory monocytes and DC2s,Cell 178, 714–730, July 25, 2019 719
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Figure 4. Cell-Specific Expression Changes in UC Highlight Metabolic Reprogramming in Epithelial Cells
(A) Induction of the kynurenine pathway in epithelial cells in UC. Shown are DE genes (rows) from the kynurenine pathway (left) in inflamed versus healthy samples
across cell subsets (columns). Dot size, fraction of expressing cells in healthy (gray outline) or inflamed (black outline) samples; dot color, significant DE model
coefficients (q < 0.05, Model-based Analysis of Single Cell Transcriptomics (MAST) hurdle model, discrete coefficient).
(B) Metabolic reprogramming of enterocytes in UC. Shown are expression changes of KEGG pathways (rows) captured by a mixed linear model (color bar) in
inflamed versus healthy samples for epithelial subsets (all subsets in Figure S5C). black outlines, q < 0.05.
(C) CD8+IL-17+ T cells induce IL17A/F, IL23R, and cytotoxic, co-stimulatory, and co-inhibitory programs in UC. Shown is the distribution of gene and program
expression (y axis) in T cells (x axis) from healthy (left), non-inflamed (center), and inflamed (right) samples (Wilcoxon test, *p = 0.05, **p = 0.01, ***p = 0.001);
crossbar: mean.
(D) IL17A expression by CD4+CD8+ cells. Shown are representative image of combined smFISH and IFA of CD4, CD8, and IL17A in inflamed human colon TMA
(left), showing (inset) CD4+CD8IL17A+ (yellow outlines; top panels, from the yellow inset) and CD4+CD8+IL17A+ (red outlines, bottom panels, from the red inset)
cells. Insets, 35 magnification.
(E) Number ofCD4CD8+IL17A+ orCD4+CD8+IL17A+ cells in the field of view (250 mm2). n = 5 samples per condition (*p < 0.05, ***p < 104, t test; error bars: SEM).
See also Figure S5.
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Figure 5. IAFs and Monocytes Are Associated with Anti-TNF Drug Resistance via OSM Signaling
(A and B) Treg cells become major sources of TNF expression in UC.
(A) Fraction of total TNF transcripts (mean across samples, y axis) expressed by each cell subset in healthy, non-inflamed, and inflamed samples (x axis). Top
expressing subsets are highlighted (legend).
(legend continued on next page)
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whereasOSMRwasmost enriched in IAFs (validated in situ; Fig-
ure 5C). Together with the expansion of these subsets during
inflammation, this led us to hypothesize that cellular remodeling
of the colon may explain, in part, the relationship between OSM
and drug resistance.
We therefore scored cell subsets for gene signatures of anti-
TNF resistance and sensitivity based on a meta-analysis of
bulk expression data from 60 responders and 57 non-re-
sponders to therapy (Wang et al., 2016; STAR Methods). The
drug resistance signature was strongly enriched in IAFs, inflam-
matory monocytes, and DC2 cells (Figures 5D and 5E) and
the drug sensitivity signature in epithelial cells (Figure 5D). The
three genes most associated with drug resistance—IL13RA2,
TNFRSF11B, and IL11—are IAF markers that are rarely ex-
pressed in other cells (Figure 5E). An inverse analysis, using
the IAF gene signature to infer the pre-treatment levels of IAFs
in bulk expression data from 20 drug responders versus 27
non-responders (Figure 5F; STAR Methods), confirmed that
IAFs are enriched in patients who are resistant to anti-TNF.
Therefore, IAFs may be implicated in the OSM-mediated resis-
tance reported by West et al. (2017).
Potential resistance mechanisms are that OSM synergizes
with TNF (West et al., 2017) or phenocopies it. To test these hy-
potheses, we examined the relationship between TNF and OSM
signaling across cell subsets. The signatures were strongly
correlated across cell subsets (even after removing shared
genes), and both were correlated to the drug resistance signa-
ture (Figure 5G). This suggests that OSMphenocopies TNF, acti-
vating downstream targets in IAFs. IAFs and inflammatory
monocytesmay thus compensate during TNF blockade, contrib-
uting to resistance.
Rewiring of Cell-Cell Interactions via Inflammation-
Associated Cell Subsets during Disease
To more generally chart the rewiring of cell-cell interactions dur-
ing colitis, we mapped receptor-ligand pairs (Ramilowski et al.,
2015) onto cell subsets to construct a putative cell-cell interac-
tion network across disease states (Figures 6A–6C), and identi-
fied pairs of cell subsets with significantly more receptor-ligand
connections than in a null model (STAR Methods).
Healthy interactions delineated distinct cellular compartments
(Figure 6A), whereas DE genes during disease targeted inter-(B) TNF expression by Treg cells during inflammation. Left: representative image of
TMA. FOXP3+IL10+TNF (yellow outlines; top right, from the yellow inset) and F
highlighted. Inset, 35 magnification; blue dashed lines, crypt position in the tissu
samples per condition (**p < 0.005, t test; error bars: SEM).
(C) OSM and OSMR expression by MHCII+ myeloid cells and IAFs, respectively.
healthy (left) and inflamed (right) human colon. Top: MHC class II+ myeloid cells
arrows. Scale bars, 50 mm. Inset, 35 magnification.
(D–G) IAF, inflammatory monocyte, and DC2 subsets are associated with anti-TN
(D) Distribution of signature scores (x axis) for anti-TNF resistance (left) and sens
(E) Mean expression level (color) and fraction of cells (dot size) expressing genes in
bar) in select cell subsets (rows). Arrows, genes whose highest expression is in I
(F) Distribution of signature scores for cell subsets (x axis) in bulk RNA-seq (Arijs
sponders, and healthy controls (Wilcoxon test, ***p < 0.001); boxplots: 25%, 50%
(G) Signature scores (mean log2[TP10K+1]) for TNF signaling (KEGG) (x axis) v
signaling (right, y axis) in each cell subset (dots) labeled by lineage (color) and m
See also Figure S5.
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6B and 6C), with UC-associated subsets acting as key network
hubs (Figure 6D). In healthy mucosa, interactions largely re-
flected gut homeostasis (e.g., DC1 cells and T cells; Figure 6A;
p < 0.05). Conversely, non-inflamed interactions were enriched
between epithelial cells and fibroblasts and T cells (Figure 6B;
all p < 104), whereas inflamed tissue showed re-wiring of inter-
actions between B cells and T cells and macrophages and
CD8+IL-17+ T cells (Figure 6C; all p < 104). UC-associated sub-
sets (e.g., M-like cells, IAFs, and inflammatory monocytes) were
the most central nodes in the network (Figure 6D), indicating that
they mediate signals between diverse cell subsets.
Cell-Cell Interactions Predict the Infiltration,
Proliferation, and Differentiation of Cell Subsets during
Inflammation
We hypothesized that shifts in the proportions of cell subsets
could be explained by changes in cell-cell interaction genes ex-
pressed by other cells. To test this, we queried all cell subset
pairs, examining, for each receptor-ligand pair, whether the li-
gand’s expression level in one cell subset was correlated across
samples with the proportions of the cell subset expressing its re-
ceptor (including autocrine interactions). This analysis uncov-
ered hundreds of significant interactions (Figure 6E; Table S5;
STAR Methods).
For example, IL18 upregulation by enterocytes during inflam-
mation is correlated with increased proportions of Treg cells,
which express its receptor IL18R1 (Figure 6E; Spearman’s
r = 0.68). In mice, IL-18 both inhibits Th17 differentiation and al-
lows for Treg cell-mediated control of gut inflammation (Harrison
et al., 2015). However, the role of epithelial cells in recruiting Treg
cells to the colon is largely unknown. The frequency of entero-
cytes, which express IL22RA1, was correlated with the expres-
sion by CD4+ activated Foshi T cells of IL22, which regulates
intestinal regeneration (Pelczar et al., 2016; Figure 6E; Spear-
man’s r = 0.55). We validated this interaction in human colon
spheroid culture, where incubation with IL-22 induced an
expression program that was significantly enriched in entero-
cytes versus ISCs (Figure S6A; p < 1010; Wilcoxon test).
Other factors promote recruitment of immune cells (e.g.,
CXCL12 for B cells) and expansion of stromal cells (e.g., PDGFD
for pericytes andOSM for IAFs) or are autocrine signals that maycombined smFISH and IFA of FOXP3, IL10, and TNFA in inflamed human colon
OXP3+IL10+TNF+ (red outlines; bottom right, from the red inset) Treg cells are
e. Right: number of FOXP3+IL10+TNF+ cells in the field of view (250 mm2). n = 5
Shown are representative images of combined smFISH and IFA of TMA from
(i.e., inflammatory monocytes or DC2s), yellow arrows. Bottom: IAFs, white
F resistance.
itivity (right) in select cell subsets (y axis); crossbar: mean.
the anti-TNF resistance signature (columns, ordered by signature rank, bottom
AFs.
et al., 2009) from human colon biopsies (y axis) of drug responders, non-re-
, and 75% quantiles; error bars: SD.
ersus drug resistance (left, y axis), drug sensitivity (center, y axis), and OSM
ean proportion across samples (size).
A B C
D E
F G
Figure 6. Rewiring of Cell-Cell Interactions Explains Shifts in Cellular Proportions during Disease
(A–C) Increased decompartmentalizationwith disease. Shown are cell-cell interaction networks estimated in (A) healthy, (B) non-inflamed, and (C) inflamed tissue.
Nodes, cell subsets annotated by lineage (color) and mean proportions (size). Edges connect pairs of cell subsets with a significant excess of cognate receptor-
ligand pairs expressed (light gray, p < 0.05) or DE (dark gray, p < 0.05) in a disease state relative to a null model (STAR Methods; Table S5).
(D) Colitis-associated cell subsets are central nodes in the interaction networks. Shown is the mean betweenness centrality (x axis) for each cell subset (y axis)
across healthy, non-inflamed, and inflamed networks, showing the 10 highest-ranked cell subsets and the mean across all other subsets (bottom bar).
(E–G) Receptor-ligand interactions explain changes in cell proportions.
(E) Each panel shows, for a pair of cells connected by a receptor-ligand interaction, the mean expression level of the ligand in one cell subset (x axis)
and the logit-transformed proportion of the cell subset expressing the receptor (y axis) in each sample, labeled by disease state (color). Dashed line, best
linear fit.
(F) Example LASSO model explaining the change in CD8+IL-17+ T cell proportions across samples as a function of positive (dark arrows) and negative (light
arrows) relationships with ligands (edge label) expressed by other cell subsets colored by lineage.
(legend continued on next page)
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regulate cell survival, proliferation, or death (e.g., MST1 for
BEST4+ enterocytes and TNFSF10 for post-capillary venules)
(Figure 6E). Last, we developed a least absolute shrinkage and
selection operator (LASSO) regression model to identify circuits
spanning multiple cell types (Figures 6F, 6G, S6B, and S6C;
STAR Methods). For example, CD8+IL-17+ T cell proportions
are explained by a combination of autocrine and paracrine inter-
actions involving epithelial cells, T cells, fibroblasts, and glia
(Figure 6F).
Many IBD Risk Genes Are Cell Type or Lineage Specific
and Differentially Expressed in Disease
To interrogate IBD genetics using scRNA-seq, we studied 151
risk loci for IBD and UC spanning 346 candidate risk genes
(STAR Methods). For most loci, the gene underlying the associ-
ation signal is unknown; however, in some cases, it is possible to
implicate a single gene because it contains a fine-mapped or
nonsynonymous coding variant or is resolved to a region of link-
age disequilibrium with no other genes. Using this approach, we
compiled a set of 57 ‘‘GWAS-implicated’’ risk genes that have a
high likelihood of being causally associated with IBD (Table S6;
STAR Methods).
Mapping these 57 GWAS-implicated risk genes onto our atlas
revealed 29 that were enriched in specific lineages (Figure 7A)
and 36 that were significantly DE during disease (Figures S7A
and S7B). In addition to known associations (e.g., NKX2-3 in
microvascular cells and HNF4A in enterocytes) (Stegmann
et al., 2006; Wang et al., 2000), we discovered several new rela-
tionships (Table S6). For example, intelectin 1 (ITLN1), a lipid raft
protein that localizes to the epithelial brush border (Wrackmeyer
et al., 2006), is enriched in immature goblet cells. Some cell sub-
sets are enriched for the expression of several GWAS-implicated
risk genes (Figure 7B). Notably, M-like cells express many risk
genes at higher levels than other cells (e.g., NR5A2, CCL20,
and JAK2; Figure 7A; Table S6), suggesting that M-like cell
dysfunction may play an important role in the disease.
Co-variation of Gene Expression within a Cell Type
Helps Predict Functions for IBD Risk Genes
We hypothesized that variation in gene expression across single
cells of the same subset can power us to infer the functions of
IBD risk genes. Past approaches often use ‘‘guilt by association’’
across bulk tissue samples but cannot distinguish changes in
expression from changes in cell proportions. In contrast, we
measured the covariation of genes across single cells within a
cell subset, allowing us to isolate co-regulated processes in
those cells (Tanay and Regev, 2017; STAR Methods).
In this way, we constructed gene modules for the 57 GWAS-
implicated IBD risk genes in all expressing cell subsets and
annotated them with putative functions (Table S6; STAR
Methods). For example, within healthy epithelial cells, the
C1orf106 module was enriched for tight junction and adherens(G) The fraction of variance (y axis) in the proportion of each cell subset (x axis)
Methods) and distribution of this statistic in 100 null models (black dots; STAR M
ordered from left by decreasing fraction of variance explained.
See also Figure S6 and Table S5.
724 Cell 178, 714–730, July 25, 2019junction genes (q < 106 and 102, respectively; Fisher’s exact
test). We recently showed that C1orf106 is involved in cell-cell
junctions (Mohanan et al., 2018).
Multiple IBD Risk Genes Co-localize in Shared Gene
Modules, Revealing Key Pathways in IBD
In many cases, multiple putative IBD risk genes were members
of the same gene module, allowing us to define 10 ‘‘meta-
modules’’ spanning over 50% of GWAS-implicated IBD risk
genes, which may reflect key disease pathways (empirical
q < 0.05; Figure 7C; Table S7; STAR Methods). For example,
the PRKCB meta-module in healthy macrophages contains 5
other risk genes (GPR65, ADCY7, PTGER4, PTPRC, and
SH2B3) and may regulate macrophage activation through cyclic
AMP (cAMP) signaling. In addition, the JAK2 meta-module in
UC-associated M-like cells contains 4 other risk genes
(CCL20, PTGER4, SH2B3, and AHR) and may regulate TNF
signaling in M-like cells.
Single-Cell Expression and Co-expression Help
Nominate Causal Genes across GWAS Loci
The functional coherence of IBD risk genes suggests that single-
cell expression or co-expression can help pinpoint genes that
underlie the signal of association at loci with multiple candidate
genes. To this end, we identified 20 IBD and UC risk regions
(each spanning more than 1 gene) whose candidate gene sets
contain a GWAS-implicated risk gene, which we term the ‘‘cor-
rect’’ gene for that region (STARMethods). For each such region,
we then tested whether the degrees of (1) expression, (2) differ-
ential expression, or (3) co-expression with other candidate
genes (iteratively defined across loci; STAR Methods) could
recover the ‘‘correct’’ risk gene for the region, relative to a null
model in which a gene is randomly selected (STAR Methods).
The null model had 33% accuracy, which did not improve
when we selected the gene with the largest DE coefficient in
either disease state (Figure 7D). However, our predictions signif-
icantly improved when we selected the gene with the highest
expression in any cell subset (Figure 7D; 55% accuracy, empir-
ical p = 0.03) or belonging to the largest module of other candi-
date genes (Figure 7D; 63% accuracy, empirical p = 0.001). For
CD loci, no method significantly outperformed the null model
(Figure 7D), suggesting that the unique risk genes for UC and
CD are active in distinct locations or only in diseased tissue.
Finally, we used this co-expression approach to nominate
causal genes across all IBD/UC risk loci, including 56 for which
the genes driving the association are unknown (Figure 7E; Table
S7). We recovered many known IBD and UC risk factors (e.g.,
HNF4A, IFIH1, and GPR35) but failed to identify others (e.g.,
RNF186; Figure 7E), highlighting the limitations of our approach
(Discussion). In addition, this analysis yielded predictions for 53
genes that were not in the GWAS-implicated set, including
RORC, ITGAV, and SMURF1 (Figure 7E).explained by a LASSO model of cell-cell interactions as in (F) (red dot; STAR
ethods). Only subsets with a significant model (empirical p < 0.05) are shown,
A B
C
D
E
In
fla
m
ed
, m
ea
n 
lo
g
Healthy, mean log
Figure 7. Modules of Co-regulated Risk Genes Help Predict Genes, Pathways, and Cell Types Targeted by IBD
(A) Cell type-specific expression of putative IBD risk genes. Shown is the mean expression of GWAS-implicated IBD risk genes (columns) across cell subsets
(rows) that were identified as cell- or lineage-specific in both healthy andUC cells (left), only in healthy cells (center), or only in UC cells (right). Asterisks, geneswith
significantly changed specificity between health and UC.
(B) Induction of putative IBD risk genes in specific subsets in disease. Shown is the mean expression of GWAS-implicated IBD risk genes across cell subsets
(marked by lineage, color) in healthy (x axis) and inflamed (y axis) samples.
(C) Functional annotation of putative IBD risk genes by co-expression meta-modules within a cell subset. Shown are the number (bottom x axis) and percent (top
x axis) of GWAS-implicated IBD risk genes captured (solid line) by successive addition of each meta-module seeded by an IBD risk gene (y axis) using
(legend continued on next page)
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DISCUSSION
By leveraging scRNA-seq in a clinical context, we assessed
cellular composition, gene expression, cell-cell interactions,
and IBD risk gene pathways in specific cell subsets from intesti-
nal biopsies. Although distinguishing cause from effect is chal-
lenging, relating single-cell data to clinical responses (e.g.,
IAFs), cell-cell interactions (e.g., enterocytes and T cells),
or risk gene expression (e.g., M-like cells) can help inform dis-
ease etiology and highlight new opportunities for therapeutic
intervention.
M-like cells were rarely detected at baseline but expanded
during inflammation and acted as hubs in the cell-cell interaction
network (Figure 6D; S3A and S3D). This expansion may reflect
tertiary lymphoid tissue or sentinel cells (Mabbott et al., 2013).
M-like cells had the highest expression of GWAS-implicated
risk genes (Figures 7A and 7B), including CCL20, whose expres-
sion was correlated to Treg cell frequencies across samples
(Table S6). They had the largest module of predicted risk genes
(Table S7), enriched in endocytosis and Th17 differentiation
genes (q < 103, Fisher’s exact test), which may reflect transcy-
tosis and delivery of antigens.
CD8+IL-17+ T cells and Tregs expand from healthy to non-in-
flamed to inflamed tissue (Figure 2A) and becomemajor sources
of IL-17 (Figure 4C) and TNF (Figure 5A,B) during inflammation,
respectively. The former may contribute to T cell pathogenicity
and tissue damage (Figures 4D and 4E; 66% co-express CD4).
Although the latter may have adopted an effector-like state,
they are still more enriched for Treg cell markers (e.g., FOXP3,
CTLA4, and IL10) than TNF– Treg cells (data not shown). Future
work will determine whether TNF+ Treg cells contribute to disease
pathology or anti-TNF resistance (Atreya et al., 2011), as well as
the role of CD8+ T cell plasticity in gut inflammation.
OSM signaling was implicated in anti-TNF resistance via un-
known myeloid and stromal cell types (West et al., 2017). Here
we show that inflammatory monocytes and IAFs may mediate
resistance via expression of OSM and OSMR, respectively (Fig-
ure 5D). In particular, IAFs were enriched in pre-treatment sam-
ples from anti-TNF non-responders (Figure 5F). In addition, we
identified that OSM phenocopies TNF, which may explain anti-
TNF resistance. Future work will determine whether IAFs are a
robust biomarker of drug response or whether combining anti-
TNF drugs with inhibition of IAF cytokines and/or receptors can
reduce anti-TNF resistance in UC patients.
IAFs uniquely express IL11, a potential therapeutic target for
fibrosis (Schafer et al., 2017), suggesting involvement in gut
fibrosis. Because they express crypt-associated (WNT2B+) and
villus-associated (WNT5B+) markers (Figures 1I and S3E), IAFs
may reflect a distinct fibroblast state. IAFs express severalhealthy (blue) or UC (red) cells relative to a null model (dashed line). Left labels,
meta-module.
(D and E) Meta-modules help nominate causal IBD risk genes from GWAS risk lo
(D) Mean number of correct predictions (left y axis) andmean percent accuracy (rig
to CD (right) for several methods based on scRNA-seq relative to the null model
(E) Nominated risk genes. Shown are loci containing GWAS-implicated IBD risk g
single gene (gold), and all other loci (green). Incorrect predictions are annotated
See also Figure S7 and Tables S6 and S7.
726 Cell 178, 714–730, July 25, 2019CAF markers, and IAF markers are enriched in CRC tumors (Fig-
ure S5B), suggesting a shared origin and/or state. IAF expansion
during cancer-associated inflammation may affect the tumor
microenvironment. Last, both IAFs and inflammatory monocytes
form hubs in the cell-cell interaction network and may affect the
proportions of other cells (Figure 6E; Table S5).
By leveraging single-cell co-expression, we mapped more
than 50% of risk genes onto 10 meta-modules (Figure 7C)
and used these meta-modules to nominate causal risk genes
across loci (Figure 7E). However, this approach may fail to
identify risk genes that are lowly expressed, active in cells
and/or tissues that were not profiled, or not co-expressed
with other risk genes. It may also fail when multiple risk genes
act at the same locus; however, we find that it improves predic-
tions even when scoring genes irrespective of region (rather
than selecting one gene per region) (Figure S7D; STAR
Methods). We hope that these analyses will pave the road for
combining human genetics and single-cell genomics to better
understand polygenic disorders by relating risk gene modules
to polygenic risk scores, mapping variants to single-cell pheno-
types, and mapping non-coding variants to cells via single-cell
allele-specific expression and expression quantitative trait loci
(eQTL) analyses.
Our work provides a framework for using scRNA-seq to under-
stand human diseases and their therapeutic responses. We
identify changes in cell proportions and gene expression with
disease state and integrate these to understand mechanisms
of cell-cell signaling and drug susceptibility. Finally, we nominate
risk genes across loci, predicting their cells of action and putative
functions, and assemble them into the core pathways that un-
derlie disease.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Patients and tissue samples
Biopsy samples were obtained from Crohn’s disease (CD) patients, ulcerative colitis (UC) patients, and healthy individuals after
informed consent and approval to the Prospective Registry in Inflammatory Bowel Disease Study at Massachusetts General Hospital
(PRISM:2004P001067). Clinical information and metadata for the samples are provided in Table S1. Healthy controls were recruited
at the time of routine colonoscopy. Healthy controls were individuals without a history of inflammatory bowel disease (IBD), a 1st de-
gree relative with IBD, histories of autoimmune disease, immunemediated conditions, infectious colitis, and colon cancer, or a family
history of colon cancer, and who were overall healthy with no other disease history (Table S1). UC patients were included based on
having a clinical diagnosis of ulcerative colitis, and observed to have active disease via macroscopic assessment from a physician
during an endoscopy. Two biopsies were obtained during endoscopy, using biopsy forceps that were used in standard of care. Each
patient’s biopsies were collected in a region determined by the scoping physician. Healthy individuals had two bites of endoscop-
ically normal tissue, while UC patients had either (1) one non-inflamed and one inflamed region biopsied (15 patients; Table S1) or two
adjacent non-inflamed and two adjacent inflamed biopsies to account for intra-patient variability (3 patients; Table S1). Biopsy bites
were immediately placed into cryovials containing Advanced DMEM F-12 and placed on ice for transport.
For scRNA-seq, all biopsy samples were obtained from UC patients and healthy individuals, including both males and females
(Table S1) while spanning a range of ages (20 – 77 years). For human spheroid cultures, biopsies were obtained from IBD patients
(2 CD patients (right colon, males and non-smokers) and a UC patient (right colon, female and non-smoker)).
METHOD DETAILS
Single cell dissociation from fresh biopsies
Single-cell suspensions from collected biopsy bites were obtained using a modified version of a previously published protocol (Pers-
son et al., 2013) as detailed below. Typically, two biopsies from the same patient were received directly in hand and processed in
parallel with an average time from patient to loading on the 10X GemCode or Chromium platform of 2.5 total hours, and never
exceeding 3.5 hours. While intact, biopsy bites were handled using a P1000 pipette applying gentle suction, and all centrifugation
steps done in a temperature controlled 4C centrifuge. Biopsy bites were first rinsed in 30 mL of ice-cold PBS (ThermoFisher
10010-049) and allowed to settle. Each individual bite was then transferred to 10 mL epithelial cell solution (HBSS Ca/Mg-Free
[ThermoFisher 14175-103], 10 mM EDTA [ThermoFisher AM9261], 100 U/ml penicillin [ThermoFisher 15140-122], 100 mg/mL strep-
tomycin [ThermoFisher 15140-122], 10 mM HEPES [ThermoFisher 15630-080], and 2% FCS [ThermoFisher 10082-147]) freshly
supplemented with 200 mL of 0.5M EDTA. Separation of the epithelial layer from the underlying lamina propria was performed for
15 minutes at 37C in a rotisserie rack with end-over-end rotation. The tube was then removed and placed on ice immediately for
10 minutes before shaking vigorously 15 times. Visual macroscopic inspection of the tube at this point yielded visible epithelialCell 178, 714–730.e1–e13, July 25, 2019 e3
sheets, and microscopic examination confirmed the presence of single-layer sheets and crypt-like structures. The remnant tissue
bite was carefully removed and placed into a large volume of ice-cold PBS to rinse before transferring to 5mL of enzymatic digestion
mix (Base: RPMI1640, 100 U/ml penicillin [ThermoFisher 15140-122], 100 mg/mL streptomycin [ThermoFisher 15140-122], 10 mM
HEPES [ThermoFisher 15630-080], 2% FCS [ThermoFisher 10082-147], & 50 mg/mL gentamicin [ThermoFisher 15750-060]), freshly
supplement immediately before with 100 mg/mL of Liberase TM [Roche 5401127001] and 100 mg/mL of DNase I [Roche
10104159001]), at 37C with 120 rpm rotation for 30 minutes. During this 30-minute lamina propria (LP) digestion, the epithelial
(EPI) fraction was spun down at 400 g for 7 minutes and resuspended in 1 mL of epithelial cell solution before transferring to a
1.5mL Eppendorf tube in order to minimize time spent centrifuging and provide a more concentrated cell pellet. Cells were spun
down at 800 g for 2 minutes and resuspended in TrypLE express enzyme [ThermoFisher 12604013] for 5 minutes in a 37C bath fol-
lowed by gentle trituration with a P1000 pipette. Cells were spun down at 800 g for 2 minutes and resuspended in ACK lysis buffer
[ThermoFisher A1049201] for 3 minutes on ice to remove red blood cells, even if no RBC contamination was visibly observed in order
to maintain consistency across samples. Cells were spun down at 800 g for 2 minutes and resuspended in 1 mL of epithelial cell so-
lution and placed on ice for 3 minutes before triturating with a P1000 pipette and filtering into a new Eppendorf tube through a 40 mM
cell strainer [Falcon/VWR 21008-949]. Cells were spun down at 800 g for 2 minutes and then resupended in 200 mL of epithelial cell
solution and placed on ice while final steps of LP dissociation occurred. After 30 minutes, the LP enzymatic dissociation was
quenched by addition of 1ml of 100% FCS [ThermoFisher 10082-147] and 80 mL of 0.5M EDTA and placing on ice for five minutes.
Samples were typically fully dissociated at this step and after gentle trituration with a P1000 pipette filtered through a 40 mM cell
strainer into a new 50 mL conical tube and rinsed with PBS to 30 mL total volume. This tube was spun down at 400 g for 10 minutes
and resuspended in 1 mL of ACK and placed on ice for 3 minutes. Cells were spun down at 800 g for 2 minutes and resuspended in
1 mL of epithelial cell solution and spun down at 800 g for 2 minutes and resuspended in 200 mL of epithelial cell solution and placed
on ice.
Human spheroid cultures for IL-22-enterocyte interaction validation
Human biopsies from IBD patients (i.e., 2 CD patients and 1 UC patient, see above) were collected for spheroid culture. Each
individual bite was minced and then transferred to 10 mL epithelial cell solution (HBSS Ca/Mg-Free [ThermoFisher 14175-103],
8 mM EDTA [ThermoFisher AM9261], 100 U/ml penicillin [ThermoFisher 15140-122], 100 mg/mL streptomycin [ThermoFisher
15140-122], 10mMHEPES [ThermoFisher 15630-080]). Separation of the epithelial layer from the underlying lamina propria was per-
formed for 40 minutes at 4C in a rotisserie rack with end-over-end rotation. The tube was then removed and placed on ice imme-
diately for 10 minutes before shaking vigorously 15 times. Visual macroscopic inspection of the crypt-like structures was performed.
Crypt like structures were spun down at 200 g for 3 minutes and washed twice with cold PBS and subsequently were resuspend with
Matrigel. Cells were then seeded in 24 well plates and grow with 50% L-WRN media (50% base –Advanced DMEM/F12 [GIBCO
12634-010] + 10% FBS, P/S, GluM, HEPES) +10uM Y27632 [TOCRIS 1254] +10uM SB 431542 [TOCRIS 1614] for 3 days before first
splitting. Media was then changed every 2 days.
For IL-22 stimulation, spheroids were grown for 3 days and then split 1:3 with fresh media containing 20ng/ml recombinant human
IL-22 [Peprotech 200-22] or mock. After 3 days, spheroids were collected and subjected to bulk RNA-Seq with the SMART-Seq2
protocol (Picelli et al., 2014).
Droplet-based scRNA-Seq
Single cells were processed through the GemCode Single Cell Platform per manufacturer’s recommendations using the GemCode
Gel Bead, Chip and Library Kits (V1) or single-cell suspensions were loaded onto 30 library chips as per the manufacturer’s protocol
for the Chromium Single Cell 30 Library (V2 and V3) (10X Genomics; PN-120233) (Table S1). Briefly, single cells were partitioned into
Gel Beads in Emulsion (GEMs) in the GemCode or Chromium instrument with cell lysis and barcoded reverse transcription of RNA,
followed by amplification, shearing (for V1) or enzymatic fragmentation (for V2 and V3) and 50 adaptor and sample index attachment.
Each biopsy bite was sequenced on two channels of the 10X GemCode or Chromium Single Cell Platform, one for the epithelial frac-
tion and the other for the lamina propria fraction in order to recover sufficient numbers of epithelial and lamina propria cells for down-
stream analyses. An input of 6,000 single cells was added to each channel with a recovery rate of approximately 2,000 cells. Libraries
were sequenced on an Illumina Nextseq or Hi-Seq (Table S1).
SMART-Seq2 for sequencing of human colon spheroids
Libraries were prepared using a modified SMART-Seq2 protocol as previously reported (Picelli et al., 2014). RNA lysate cleanup was
performed using RNAClean XP beads [Agencourt], followed by reverse transcription with Maxima Reverse Transcriptase [Life Tech-
nologies] and whole transcription amplification (WTA) with KAPA HotStart HIFI 23 ReadyMix [Kapa Biosystems] for 16 cycles. WTA
products were purified with Ampure XP beads [Beckman Coulter], quantified with Qubit dsDNA HS Assay Kit [ThermoFisher], and
assessed with a high sensitivity DNA chip [Agilent]. RNA-Seq libraries were constructed from purified WTA products using Nextera
XT DNA Library Preparation Kit [Illumina, FC-131-1096]. The population and no-cell controls were processed using the samemethod.
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Immunofluorescence assay (IFA)
Staining of human colon samples from tissue array of inflamed and healthy individuals (TMA, US BioMAX, #CO809a and #CO245)
was conducted as previously described (Biton et al., 2011). Sections were deparaffinized with standard techniques, incubated
with primary antibodies overnight at 4C, and then incubated with secondary antibodies at room temperature for 30 min. Slides
were mounted with Slowfade Mountant+DAPI (Life Technologies, S36964) and sealed.
Single-molecule fluorescence in situ hybridization (smFISH)
RNAScope Fluorescent Multiplex and RNAScope Multiplex Fluorescent v2 (Advanced Cell Diagnostics) were used per manufac-
turer’s recommendations with the following alterations. Target retrieval boiling time was adjusted to 12 minutes and incubation
with Protease IV at 40C was adjusted to 15 minutes. Slides were mounted with Slowfade Mountant+DAPI (Life Technologies,
S36964) and sealed.
Combined IFA and smFISH
Combined IFA and smFISH was implemented by first performing smFISH and then IFA, as described above, with the following
alterations. After horseradish peroxidase (HRP) enzyme blocking, tissue sections were washed in washing buffer, incubated with pri-
mary antibodies overnight at 4C, washed in 1x TBST 3 times and then incubated with secondary antibodies for 30 min at room tem-
perature. Slides were mounted with Slowfade Mountant+DAPI (Life Technologies, S36964) and sealed.
Imaging of tissue sections
Images of tissue sections were taken with a confocal microscope Fluorview FV1200 using Kalman filtering and sequential laser emis-
sion to reduce noise and signal overlap. Scale bars were added to each image using the confocal software FV10-ASW 3.1 Viewer.
Images were overlaid and visualized using ImageJ software (Schneider et al., 2012).
Antibodies and RNA smFISH probes
Antibodies used for immunofluorescence
Mouse anti-EPCAM (1:500, ThermoFisher MA1-06502), mouse anti-Vimentin (1:500, Millipore MAB3400), mouse anti-CD19 (1:100,
BioLegend 302201), rat anti-CD45 (1:200, ThermoFisher MA5-17687), goat anti-CD138 (1:100, R&D Systems AF2780), mouse anti-
HLA-DR/DP/DQ (1:200, ThermoFisher MA1-25914), mouse anti-CD11c (1:100, BD Biosciences 550375), goat anti-CD4 (1:100, R&D
Systems AF-379-NA), rabbit anti-CD8 (1:100, Invitrogen SP16). Alexa Fluor 488-, 594-, and 647-conjugated secondary antibodies
were used (Life Technologies).
Human probes used for single-molecule FISH with RNAscope (Advanced Cell Diagnostics):
BEST4 (C1), KRT19 (C2), RSPON3 (C1), GREM2 (C2), IL13RA2 (C1), PLAU (C3), HLA-DRA (C1), OSM (C1), HLA-DPB1 (C2), OSMR
(C2), SOX8 (C1), CCL20 (C2), IL17A (C1).
QUANTIFICATION AND STATISTICAL ANALYSES
Processing FASTQ reads into gene expression matrices
Cell Ranger v2.0 was used to demultiplex the FASTQ reads, align them to the hg19 human transcriptome, and extract their ‘‘cell’’ and
‘‘UMI’’ barcodes. The output of this pipeline is a digital gene expression (DGE) matrix for each sample, which records the number of
UMIs for each gene that are associated with each cell barcode. DGE matrices were filtered to remove low quality cells, defined as
cells in which fewer than 250 different genes were detected. This cutoff was determined empirically: higher cutoffs led to dispropor-
tionate filtering of mast and T cells, whereas lower cutoffs did not affect the cell type distribution, but did reduce overall data quality.
To account for differences in sequencing depth across cells, UMI counts were normalized by the total number of UMIs per cell and
converted to transcripts-per-10,000 (henceforth ‘‘TP10K’’).
Cell clustering overview
To cluster single cells into distinct cell subsets, we followed the general procedure outlined in Haber et al. (2017) with additional mod-
ifications. This workflow includes the following steps: partitioning cells into epithelial, stromal, and immune compartments, followed
by clustering the cells within each compartment, which entails the selection of ‘‘variable’’ genes, batch correction, dimensionality
reduction (PCA), and graph clustering. Each step of this workflow is detailed below.
Partitioning cells into epithelial, stromal, and immune compartments
Cells were partitioned into epithelial, stromal, and immune compartments based on the expression of knownmarker genes. First, we
clustered the cells within each sample by their gene expression profiles (with the clustering procedure below). The clusters were
scored for the following gene signatures: epithelial cells (EPCAM, KRT8, KRT18), stromal cells (COL1A1, COL1A2, COL6A1,
COL6A2, VWF, PLVAP, CDH5, S100B), and immune cells (CD52, CD2, CD3D, CD3G, CD3E, CD79A, CD79B, CD14, CD16,
CD68, CD83, CSF1R, FCER1G). Signature scores were calculated as the mean log2(TP10K+1) across all genes in the signature.
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the accurate segregation of cells. Finally, the cells within each compartment were assembled into three DGEmatrices, comprising all
epithelial cells, all stromal cells, and all immune cells.
Variable gene selection
To identify variable genes within a sample, we first calculated the mean (m) and the coefficient of variation (CV) of expression of each
gene. Genes were then grouped into 20 equal-frequency bins (ventiles) according to their mean expression levels. LOESS regression
was used to fit the relationship, log(CV) log(m), and the 1,500 genes with the highest residuals were evenly sampled across these
expression bins. To extend this approach to multiple samples, we performed variable gene selection separately for each sample to
prevent ‘‘batch’’ differences between samples from unduly impacting the variable gene set. A consensus list of 1,500 variable genes
was then formed by selecting the genes with the greatest recovery rates across samples, with ties broken by random sampling. This
consensus gene set was then pruned through the removal of all ribosomal, mitochondrial, immunoglobulin, and HLA genes, which
were found to induce unwanted batch effects in some samples in downstream clustering steps.
Batch correction
We observed substantial variability between cells that had been obtained from different human subjects, which likely reflects a com-
bination of technical and biological differences. In some cases, these ‘‘batch effects’’ led to cells clustering first by patient or disease
phenotype, rather than by cell type or cell state. To eliminate these batch differences, we ran ComBat (Johnson et al., 2007) with
default parameters on the log2(TP10K+1) expressionmatrix, allowing cells to be clustered by cell type or cell state. Importantly, these
batch-corrected data were only used for the PCA and all steps relying on PCA (e.g., clustering, diffusion map, t-SNE visualization); all
other analyses (e.g., differential expression analysis) were based on the original expression data.
Comparison of batch correction methods
We compared ComBat to two other batch correction methods that were designed specifically for scRNA-Seq data: MultiCCA (Butler
et al., 2018) and LIGER (Welch et al., 2018). Bothmethods were run on the log2(TP10K+1) expression data for cells from the epithelial,
stromal, and immune compartments, using default parameters with n = 20 components to match the original analysis. Following
batch correction, cell embeddings were visualized using the Barnes-Hut t-Distributed Stochastic Neighbor Embedding (t-SNE) algo-
rithm with default parameters. To visualize congruence between methods, we then projected the cell subsets that were originally
defined using the ComBat-transformed data (i.e., Figure 1C) onto the t-SNE coordinates calculated using each of the other methods.
Inspection of the batch correction methods revealed that ComBat performed well in comparison to the other methods, in agreement
with a recent comparison of batch correction methods (Büttner et al., 2019).
Dimensionality reduction, graph clustering, and t-SNE visualization
Cells were clustered at two stages of the analysis: first, to initially partition the cells within each sample into epithelial, stromal, and
immune compartments (single sample clustering), and second, to cluster cells from multiple samples into distinct subsets (multi-
sample clustering).
For single-sample clustering, we first ran low-rank PCA on the variable genes of the entire log2(TP10K+1) expression matrix (as no
consensus list needs to be generated). The Infomap graph clustering algorithm (Rosvall and Bergstrom, 2008) was then applied to the
k-nearest neighbor (k-NN) graph defined using PCs 1 to 20 and k = 50 nearest neighbors. These parameters were chosen to ‘‘over-
cluster’’ the cells, ensuring that cells from distinct compartments were not grouped together.
In contrast, for multi-sample clustering, we ran low-rank PCA on the variable genes of the batch-corrected expression matrix, cho-
sen as described above. We then applied Phenograph (Levine et al., 2015) to the k-NN graph defined using PCs 1 to 20 and a varying
k, which was selected through close inspection of the data (see ‘‘Selecting the number of nearest neighbors for graph clustering’’):
k = 750 for epithelial cells, k = 250 for stromal cells, and k = 250 for immune cells. Althoughmost clusters were stable over a range of k,
some rare epithelial subsets, such as tuft cells and M cells, were initially merged with larger clusters. We therefore re-clustered the
epithelial cells with fewer neighbors (k = 50) to achieve higher granularity in the clusters and added clusters corresponding to BEST4+
enterocytes, enteroendocrine cells, and M cells to the original set of clusters. Additionally, we partitioned the immune cells into
myeloid, B cell, and T cell compartments based on DE genes within each cluster, and repeated the clustering using the k-NN graphs
defined with PCs 1 to 15 and k = 50 for myeloid cells, k = 100 for B cells, and k = 100 for T cells. After clustering the cells, we merged
pairs of clusters that were separated by fewer than 5 differentially expressed (DE) genes with AUC > 0.60, a permissive cutoff that
merges only highly similar clusters. Finally, the Barnes-Hut t-Distributed Stochastic Neighbor Embedding (t-SNE) algorithm was
run on the PCs with perplexity = 20 and for 10,000 iterations to produce two-dimensional embeddings of the data for visualization
(Figure 1C).
Selecting the number of nearest neighbors for graph clustering
To select the number of nearest neighbors, k, for clustering, we examined a range of choices (typically k = 25, 50, 100, 250, 500, and
750). In general, we tried to select a k yielding the highest granularity clusters that were still biologically distinct, as determined
through inspection of their marker genes. We also looked at the stability of cluster assignments over the full parameter range and
tried to select a k yielding stable and well-resolved clusters. Therefore, the final choice of k reflects both data-driven clusteringe6 Cell 178, 714–730.e1–e13, July 25, 2019
and expert knowledge. To ensure that all transcriptionally distinct cell subsets were identified, we sub-clustered each cell subset and
identified those sub-clusters that were supported by discriminative differentially expressed genes (see ‘‘Identifying transcriptionally
distinct sub-clusters’’).
Identifying transcriptionally distinct sub-clusters
To systematically determine whether transcriptionally distinct subpopulations of cells may exist, we sub-clustered each cell subset
using its k-NN graph defined using PCs 1 to 10 and k = 250 (see ‘‘Dimensionality reduction, graph clustering, and t-SNE visualiza-
tion’’). These parameters were selected to yield relatively few sub-clusters, such that that any of the major differences would be
found. We then searched for differentially expressed genes that could accurately distinguish between the cells in each sub-cluster
versus all other cells with an area under the curve (AUC) exceeding 0.75. Sub-clusters containing highly discriminative marker genes
were then flagged for further analysis (Table S2).
Comparison of training and test sets by a classification based approach
To compare the training and test sets, we first trained a Random Forest classifier to predict the subset of each cell, using the cell
subsets that were originally defined from the training set (Figure 1C). The RandomForest was trained separately for cells in the epithe-
lial, stromal, and immune compartments, with the input data constructed as follows. First, we used ComBat (Johnson et al., 2007) to
generate a batch-corrected log2(TP10K+1) expression matrix containing the variable genes (X1). Second, we performed PCA on this
matrix to obtain a 20-dimensional embedding of the batch-corrected data (X2). Third, we used LIGER to compute a separate batch-
corrected 20-dimensional embedding of the data (X3). These threematrices (i.e., X1, X2, and X3) were then combined to form the input
feature matrix, X. We note that ComBat and LIGER provide similar but complementary descriptions of the data and both sets of fea-
tureswere deemed important by theGini Importancemeasure (data not shown). The RandomForest was trainedwith 1,000 trees and
default parameters, except that in order to account for class imbalances, we weighted each class by the inverse of its class
frequency.
Across all cells, the ‘‘out of bag’’ error, which provides an unbiased estimate of the test error, was 10.7%, suggesting this model
can be used to accurately infer subsets for the test data. Classification errors were mostly between similar cell subsets (Figure S1C),
such as CD69- and CD69+ mast cells, with two major exceptions. Our model performed less well for cycling immune cells, which are
composed of cells from many different types, and CD8+IL-17+ T cells.
Next, to confirm that this model can be applied to the test dataset, we co-embedded the single cells from both datasets (see
‘‘Dimensionality reduction, graph clustering, and t-SNE visualization’’) and labeled them according to their predicted cell subsets
(Figure S1D). Following removal of doublets from the test dataset (see ‘‘Doublet removal’’), the two datasets aligned well with noma-
jor incongruences. In some cases, the merged dataset contained increased sub-cluster resolution (e.g., immature and mature
BEST4+ enterocytes versus only one cluster ofBEST4+ enterocytes), due to an increase in cell number, or discernible patient-specific
sub-clusters, but the classifier accurately classified these cells into their larger groups.
Comparison of intra- versus inter-individual variability
To assess levels of biological and technical variation in our scRNA-Seq profiles, we analyzed the epithelial and lamina propria com-
partments of 18 replicate biopsies collected from the same individual (12 healthy, 3 non-inflamed, 3 inflamed). For each pair of sam-
ples, we measured the Pearson correlation between their logit-transformed cell proportions, as well as their mean gene expression
levels. We then compared intra-individual and inter-individual correlations across healthy, non-inflamed, and inflamed tissue regions
(Figure S1E).
Doublet removal
Following the initial clustering, we removed all clusters consisting of likely cell doublets from epithelial, stromal, myeloid, B cell and
T cell compartments, then repeated the steps outlined in ‘‘dimensionality reduction, graph clustering, and t-SNE visualization.’’ Dou-
blets were identified through expert annotation of the marker gene lists for each cell cluster and corresponded to clusters with
markers from distinct lineages (e.g., clusters with B cell and T cell markers). However, within the immune compartment, cells from
distinct lineages sometimes clustered together (e.g., cycling B cells and cycling T cells) and these cells were then separated back
into their source lineages. Doublet removal was therefore an iterative process alternating between removing doublets, assigning cells
to the correct compartments, and graph clustering and t-SNE visualization.
Cell lineage dendrogram
As an auxiliary tool, cell subsets were manually organized on a dendrogram reflecting known lineage relationships (Figure 1D, top).
This tree is organized as follows. Under epithelial cells we split Absorptive and Secretory subtrees. The Absorptive subtree included
further subtrees for Transit Amplifying (TA) cells (Absorptive TA 1, Absorptive TA 2), Immature cells (Immature Enterocytes 1, Imma-
ture Enterocytes 2, Enterocyte Progenitors), and Mature cells (Enterocytes, BEST4+ Enterocytes). The Secretory subtree included
subtrees for progenitor cells (Secretory TA, Immature Goblet) and for mature cells (Goblet, Tuft, and Enteroendocrine). Stem cells,
Cycling TA cells, andM cells were placed directly under the node corresponding to all epithelial cells. The Stromal subtree had Fibro-
blast, Endothelial, and Glial subtrees. Fibroblasts were subdivided into WNT2B+ (WNT2B+Foshi, WNT2B+Foslo 1, WNT2B+Foslo 2,Cell 178, 714–730.e1–e13, July 25, 2019 e7
RSPO3+), WNT5B+ (WNT5B+ 1, WNT5B+ 2), inflammatory fibroblast, and myofibroblast subtrees. The Endothelial cell subtree
included branches for Endothelial, Microvascular, Post-capillary venules, and Pericytes. The Immune subtree was partitioned into
myeloid and lymphoid lineages. Myeloid cells included subtrees for Mast cells (CD69+ Mast, CD69- Mast) and Monocytes (Macro-
phages, Cycling Monocytes, Inflammatory Monocytes, and DCs (DC1s, DC2s)). Lymphoid cells included subtrees for NK cells, ILCs,
B cells, T cells (subdivided intoCD4+ T cells (CD4+ Activated Foslo,CD4+ Activated Foshi,CD4+ Memory, Tregs, PD1
+, MThi) andCD8+
T cells (CD8+ IELs, CD8+ LP, CD8+IL-17+, and CD8+ Cycling)), and B cells (Plasma cells, Follicular (FO) B cells, Germinal Center (GC)
B cells, and Cycling B cells).
Scoring samples for inflammation-associated genes
To validate our endoscopic assessments of tissue inflammation, we constructed a gene signature of the following inflammation-
associated genes: IFNG, IFNGR1, IFNGR2, IL10, IL12A, IL12B, IL12RB1, IL12RB2, IL13, IL17A, IL17F, IL18, IL18R1, IL18RAP,
IL1A, IL1B, IL2, IL21, IL21R, IL22, IL23A, IL23R, IL2RG, IL4, IL4R, IL5, IL6, JUN, NFKB1, RELA, RORA, RORC, S100A8, S100A9,
STAT1, STAT3, STAT4, STAT6, TGFB1, TGFB2, TGFB3, and TNF. We separately scored EPI and LP samples for these signatures,
then combined these measurements by calculating their mean z-scores. P values between healthy and non-inflamed or inflamed
samples were computed using a one-sided Wilcoxon test. P values between non-inflamed and inflamed samples were computed
using a one-sided paired Wilcoxon test within each subject.
Epithelial cell differentiation
The diffusion map and diffusion pseudotime (Figure 2D) for epithelial cells were estimated with Scanpy v0.4.2 (Wolf et al., 2018a) on
the log2(TP10K+1) expression matrix, with the following parameters: n_pcs = 20, n_neighbors = 30, n_dcs = 20, n_branchings = 1,
min_group_size = 0.001. The differentiation map (Figure 1F) was estimated using the partition-based graph abstraction (PAGA)
method implemented in Scanpy v1.4 (Wolf et al., 2018b) using the same parameters. In both cases, one of the LGR5+ISCs was
randomly selected as the root cell. To identify significant changes in epithelial cell differentiation with UC, we estimated diffusion
pseudotimes separately for absorptive and secretory cells, and used mixed effects models to assess significance (see ‘‘Identifying
significant changes in gene signatures and pseudotime during disease’’).
Estimation of cell proportions
Because EPI and LP samples were separately processed and sequenced, cell proportions estimated from each sample type are not
directly comparable. Therefore, rather than combining the cell subset proportions from different sample types (e.g., using a weighted
mean across EPI and LP samples), we determined for each cell subset whether it was EPI-associated or LP-associated and calcu-
lated its proportions using only samples of that type. As expected, EPI samples mostly consisted of epithelial cells (89% ± 15%
epithelial cells on average) with some tissue-resident immune cells, such as CD69- mast cells, CD8+ IELs, and CD8+IL-17+
T cells, whereas LP samples primarily contained immune and stromal cells (84% ± 18% immune and stromal cells on average).
Identifying statistically significant differences in cell proportions
To identify changes in cell proportions between healthy, non-inflamed, and inflamed tissue, we used multiple statistical tests that
each capture distinct but complementary types of information: (1) a Dirichlet-multinomial regression, (2) a Fisher’s exact test, and
(3) a Mann-Whitney test. We describe each of these below. A major concern with the comparison of cell proportions in scRNA-
Seq data is that they are not independent of each other. Because all proportions sum to 1, an increase in the proportion of one
cell subset will necessarily lead to a decrease in the proportions of other cell subsets. To account for these dependencies, we
used a Dirichlet-multinomial regression model, which tests for differences in cell composition between disease states (e.g., inflamed
versus healthy), while accounting for the proportions of all of the other cell subsets. This regressionmodel and its associated p values
were calculated using the ‘‘DirichReg’’ function in the DirichletReg R package. Because this is a multivariate test, its results may at
times appear counter-intuitive andmay not be congruent with univariate tests, such as a t test, which examine each cell subset inde-
pendently. We therefore also performed a Fisher’s exact test on the numbers of cells from each subset that were isolated from non-
inflamed or inflamed specimens versus healthy specimens. This test reflects how enriched each cell subset is in each disease state,
but does not account for the sample from which each cell was isolated. Therefore, we also performed a non-parametric Mann-Whit-
ney test on the proportions of each cell subset in non-inflamed or inflamed specimens versus healthy specimens.
Comparison of IgA+ and IgG+ plasma B cells
Themean log2(TP10K+1) expression levels of the IgA heavy chain genes (IGHA1, IGHA2) and IgG heavy chain genes (IGHG1, IGHG2,
IGHG3, IGHG4) were scored across all plasma cells. After examining the distribution of these scores, we empirically determined that
an expression cutoff corresponding to log2(TP10K+1) = 6 accurately discriminated among IgA
+ and IgG+ cells. In total, 94% of all
plasma cells were classified as either IgA+ or IgG+, with only 0.2% classified as IgA+IgG+ ‘‘double positive’’ cells (likely corresponding
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Downsampling single cells for mean expression analysis
To facilitate downstream analyses, a separate dataset was constructed containing 50,375 down-sampled cells. These data were
used solely for the estimation of the expression distribution within cell subsets, but all other analyses were based on the full dataset.
We verified that the mean expression levels from the full and down-sampled datasets were strongly correlated across cell subsets
(mean Pearson’s r = 0.999). To down-sample cells, we first calculated the number of cells obtained from every cell subset in each
sample. We determined a fixed number of cells to retain from each of these subset-sample groups (purposefully not preserving their
original proportions) that would yield approximately 50,000 cells in the down-sampled dataset. Finally, the highest quality cells
(measured by the number of genes per cell) were retained from each of these groups. Using this method, samples and cell subsets
with relatively many cells (e.g., plasma cells) were heavily down-sampled, whereas samples and cell subsets with relatively few cells
(e.g., tuft cells) were largely retained intact.
Differential expression analysis
Differential expression (DE) tests were performed using MAST (Finak et al., 2015), which fits a hurdle model to the expression of each
gene, consisting of logistic regression for the zero process (i.e., whether the gene is expressed) and linear regression for the contin-
uous process (i.e., the expression level). To reduce the size of the inference problem, separatemodels were fit for each level of the cell
tree (see ‘‘Cell lineage dendrogram,’’ above), comparing cells within the given group to all other cells (e.g., ISCs versus non-ISCs). The
regression model includes terms to capture the effects of the cell subset and the disease state on gene expression, while controlling
for cell complexity (i.e., the number of genes detected per cell).
Specifically, we used the regression formula, YiX+D+N, where Yi is the standardized log2(TP10K+1) expression vector for gene i
across all cells, X is a binary variable reflecting cell subsetmembership (e.g., ISCs versus non-ISCs),D is the disease state associated
with each cell, and N is the number of genes detected in each cell. Overall, we fit three types of DE models, which varied by the en-
coded disease states: (1) to identify cell subset markers and DE genes in UC patients relative to healthy controls, we used three
disease states: Healthy, UC non-inflamed, and UC inflamed; (2) to identify DE genes between non-inflamed and inflamed patient
samples, we used two disease states: UC non-inflamed and UC inflamed; and (3) to identify genes that are specific to cell subsets
in healthy subjects andUC patients, we used two disease states: Healthy andUC. Additionally, a few heuristics were used to increase
the speed of the tests: we required all tested genes to have a minimum fold change of 1.2 and to be expressed by at least 1% of the
cellswithin the group of interest, and cells were evenly downsampled across groups so that amaximum of 2,500 cells were tested for
each cell subset. In all cases, the discrete and continuous coefficients of themodel were retrieved and p values were calculated using
the likelihood ratio test in MAST. Q-values were separately estimated for each cell subset comparison using the Benjamini-Hochberg
correction. Unless otherwise indicated, all reported DE coefficients and q-values correspond to the discrete component of themodel
(i.e., the logistic regression).
Estimation of the droplet contamination rate and filtering of putative ambient RNA contaminants
Droplets encapsulate single cells with small portions of the extracellular environment, leading to low but persistent levels of contam-
ination by ambient RNA (Macosko et al., 2015). To correct for this, we explicitly modeled droplet contamination. First, we partitioned
individual cells into the following groups: epithelial cells, fibroblasts, endothelial cells, myeloid cells, B cells, and T cells. We reasoned
that each group should uniquely express a subset of genes that are not found in other cells; for example, B cells uniquely express
IGHA1 and T cells uniquely express CD3D. Therefore, the off-target expression of such genes in the incorrect group (e.g. IGHA1
expression in T cells) should reflect contamination rather than intrinsic gene expression. Moreover, we hypothesized that the levels
of such off-target gene expression could serve as an accurate indicator of contamination rates in the entire dataset. To test this hy-
pothesis, we compared themean expression levels of genes within each group (i.e., in-group expression) to a weighted mean of their
expression levels in all other cells (i.e., out-group expression), which is a proxy for the composition of extracellular RNA (e.g., B cells
versus non-B cells, Figure S1F, see ‘‘Normalization and scaling of expression levels for contamination filtering’’ below for additional
details). As expected, knownmarkers for cell groups were enriched at the edges of the point distribution, where differences between
in-group and out-group expression were greatest. For example, known B cell markers were enriched on the left edge of the point
distribution (e.g. IGHA1 and IGJ, Figure S1F), while markers for other cell types were enriched on the right edge, likely reflecting
contamination (e.g. CD3D and TPSAB1, Figure S1F). We noticed two other patterns yielding insights into contamination: (1) genes
with sufficiently high out-group expression always had non-zero in-group expression, and (2) there is a linear relationship between in-
group and out-group expression levels, particularly for contaminants on the right edge of the point distribution (Figure S1F). Taken
together, these observations suggest that contamination uniformly affects all genes and that the overall levels of contamination for
each gene are proportional to its representation in the extracellular RNA pool.
Therefore, to estimate the contamination rate for each cell group, we fit a robust linear model to the genes on the right edge of the
point distribution, whose expression is almost entirely driven by contamination. Surprisingly, the fitted models were nearly identical
across groups (slope = 1.33 ± 0.07, intercept = 7.22 ± 0.33) and we constructed a consensus model using the mean slope and
mean intercept. This model corresponds to a contamination rate between 0.5% and 5% of the total RNA pool in each sample.
We used this model to identify potential contaminants in all cell subsets by conservatively flagging genes with residuals < 5Cell 178, 714–730.e1–e13, July 25, 2019 e9
(i.e., 32-fold increase over the estimated contamination rate) and genes in each cell subset whose expression did not exceed 1% of
its total expression across all cells. This approach filtered out nearly all identifiable contamination, assessed by manual inspection of
the filtered and unfiltered gene lists.
Normalization and scaling of expression levels for contamination filtering
The composition of extracellular RNA is different for each sample; for example, EPI samples have high levels ofMUC2, while LP sam-
ples have high levels of IGHA1. Any attempt to identify droplet contamination should therefore account for the distribution of samples
that cells were isolated from. For example, the expression of genes in B cells (i.e., in-group expression) should be compared to their
pooled expression levels in non-B cells (i.e., out-group expression) using the same samples that the B cells were recovered from.
Thus, rather than using a simple mean to measure the in-group and out-group expression levels for a gene, we used a weighted
mean of its expression in each sample, where the weights were determined as the fraction of in-group cells belonging to that sample.
More specifically, the in-group expression of gene i for cell group q is:
Iiq =
X
j
wqj,
1
Tj
X
k˛qj
xikwhere xik is the expression level of gene i in cell k, qj is the set of all cells that were isolated from sample j that belong to cell group q, Tj
is the total number of cells in sample j, andwqj is theweight for cell group q in sample j. Similarly, the out-group expression of gene i for
cell group g is:
Oig =
X
j
wqj,
1
Tj
X
k˛Qj
xikwhereQ is the set of all cells that were isolated from sample j that dj o not belong to cell group q. Theweight for cell group q in sample j,
wqj, is equal to the proportion of cells from cell group q that were isolated from sample j:
wqj =
qj

P
k jqk jImportantly, the normalization factor, Tj, normalizes the expression to the total number of cells in the sample, ensuring that expression
levels are comparable across cell groups.
Gene specificity
For each expressed gene, we testedwhether that genewas specific to any cell subset (e.g., Treg cells) or any node of the cell hierarchy
dendrogram (e.g. CD4+ T cells). We defined a gene as specific to a cell group if it was significantly (i.e., adjusted p value < 0.05) and
positively differentially expressed in all pairwise comparisons to non-overlapping cell subsets and itsmean expression level within the
group was at least 2-fold higher than its mean expression in all non-overlapping cell subsets. In addition, we searched for cases
where a gene gained, lost, or changed its cell specificity between health and UC. Note that a change in gene specificity may, how-
ever, simply reflect the gain or loss of statistical power, rather than a statistically significant change in gene expression. Therefore, to
confirm that a gene was no longer specific to a cell subset in a given cohort (i.e., healthy subjects or UC patients), we required that
another cell subset have significantly greater expression of the target gene within that cohort.
Scoring gene signatures and identifying significant changes between health and disease
To prevent highly expressed genes from dominating a gene signature score, we scaled each gene of the log2(TP10K+1) expression
matrix by its root mean squared expression across all cells (using the ‘scale’ function in R with center = FALSE). The signature score
for each cell was then computed as the mean scaled expression across all genes in the signature. To identify statistically significant
changes in gene signature expression within each cell subset, we compared the change in expression of the gene signature to a null
distribution that was estimated from 100 background sets of genes. Each background gene set was selected to have matching
expression levels, using 20 equal-frequency expression bins that were defined using the healthy cells within the cell subset. Mixed
effects models were used to identify significant changes in background-adjusted expression levels (see ‘‘Identifying significant
changes in gene signatures and pseudotime with disease’’).
Estimation of false discovery rate
Unless otherwise specified, false discovery rates were estimated with the Benjamini and Hochberg correction (Benjamini and Hoch-
berg, 1995), using the ‘‘p.adjust’’ R function with the ‘‘fdr’’ method.
Identifying significant changes in gene signatures and pseudotime with disease
To identify significant changes in diffusion pseudotime (Figure 2D) or in the expression levels of gene signatures (Figure 4B) with dis-
ease, we used mixed linear models, which account for the uneven distribution of cells across samples. Mixed linear models weree10 Cell 178, 714–730.e1–e13, July 25, 2019
implemented using the ‘‘lme’’ function in the ‘‘nlme’’ R package, using a fixed effect term for disease state (i.e., healthy, non-inflamed,
or inflamed) and a random intercept that varies with each sample: Yi  D + (1 j S), where Yi is the vector of covariate i values across
cells,D is the disease state associatedwith each cell, andS is the sample that each cell was isolated from. P values for the fixed terms
were estimated with the ‘‘anova.lme’’ function.
Acquisition of gene sets
Human transcription factors were obtained TcoF-DB v2 (Schaefer et al., 2011). Human G-protein coupled receptors were obtained
from UniProtKB (search term: family = ‘‘g protein coupled receptor,’’ reviewed = ‘‘yes,’’ organism = ‘‘Homo sapiens (Human) [9606]’’)
(The UniProt Consortium, 2018). Human transporters were obtained from UniProtKB (search term: keyword = ‘‘Transport [KW-
0813],’’ reviewed = ‘‘yes,’’ organism ‘‘Homo sapiens (Human) [9606]’’). Human pattern recognition receptors were obtained from
PRRDB (Lata and Raghava, 2008) and supplemented with Human Gene Nomenclature Committee (HGNC) ‘‘C-type lectin domain
containing’’ gene family members (Yates et al., 2017). Human cytokines were obtained from the KEGG pathway for ‘‘Cytokine-cyto-
kine receptor interaction’’ (Kanehisa et al., 2017).
Acquisition of gene signatures
All pathways related to metabolism, inflammation, and stress were obtained from KEGG (Kanehisa et al., 2017), except in the
following cases, for which the pathways were not found in KEGG: IFN-a, IFN-g, and IL-2/Stat5 pathways were obtained fromMSigDB
(Liberzon et al., 2015) and the OSM pathway was obtained from WikiPathways (Slenter et al., 2018). The T cell signatures for cyto-
toxicity (GNLY, GZMB, GZMK, IFNG, NKG7), co-inhibition (CTLA4, PDCD1, TIGIT, HAVCR2, LAG3, BTLA, PDPN, CD160, GP49A,
LILRB4, CD274, CD200, CD244, PILRA, SIRPB1, LAIR1, CEACAM1, KLRA7, KLRA3. KLRA9, PTGER4, KLRD1, KLRC1, PROCR),
and co-stimulation (CD28, CD226, TNFRSF4, TNFRSF9, ICOS, CD27, TNFSF14, CD80, TNFSF4, CD86, TNFSF11, CD276,
CD40LG, TNFRSF18) were derived from known markers. Gene signatures for resistance and susceptibility to anti-TNF blockade
were obtained from a meta-analysis of 60 responders and 57 non-responders (Wang et al., 2016). The gene signature for poor colo-
rectal cancer prognosis was obtained from ameta-analysis of thousands of CRC patients, and the top 25 genes in the signature were
used (Calon et al., 2015).
Acquisition of microarray and bulk RNA-Seq datasets
We downloaded the following bulk datasets for comparison to our single-cell data: (1) microarray data from colon biopsies of 20 re-
sponders and 27 non-responders to TNF blockade, downloaded from the Gene Expression Omnibus (Arijs et al., 2009; GEO:
GSE14580); and (2) the normalized expression matrix for 414 colon adenocarcinoma samples from The Cancer Genome Atlas (Can-
cer Genome Atlas, 2012) sequenced on both the Illumina HiSeq and Illumina Genome Analyzer.
Comparison of TNF signaling and response to anti-TNF therapy
We scored each cell subset for gene signatures related to TNF signaling and response to anti-TNF therapy. To ensure that these gene
signatures were disjoint for correlation analysis, we removed all shared genes from the gene signatures related to anti-TNF response.
Analysis of bulk RNA-Seq data from human colon spheroids treated with IL-22 versus controls
To test the effects of IL-22 treatment on human colon spheroids, we constructed gene signatures for the top 100 differentially ex-
pressed genes in IL-22 treated spheroids versus non-treated controls (‘‘IL-22 signature’’). Differential expression was measured
as the mean log2(TP10K+1) fold change between the conditions across all of the bulk RNA-Seq samples. These gene signatures
were then scored to enterocytes from healthy individuals (see ‘‘Scoring gene signatures and identifying significant changes between
health and disease’’).
Using receptor-ligand pairs to infer cell-cell interactions
To identify cell-cell interactions, we mapped the FANTOM5 database of literature-supported receptor-ligand interactions (Ramilow-
ski et al., 2015) onto our lists of cell subset markers and differentially expressed genes within healthy, UC non-inflamed, and UC in-
flamed cells. We restricted our analysis to high-confidence interactions by requiring cell subset markers to have a discrete model
coefficient greater than 1 and adjusted p value less than 0.05. To identify changes in this network with disease, we also constructed
networks where the receptor and/or ligand were significantly differentially expressed, again requiring genes to have a discrete model
coefficient withmagnitude greater than 1 and adjusted p value less than 0.05. To ensure that these differentially expressed genes had
sufficiently high expression, we also required them to be cell subset markers in cells isolated from healthy subjects or the relevant
disease state (i.e., UC non-inflamed or UC inflamed).
For all networks, we quantified the interaction strength between two cell subsets as the number of unique receptors and ligands
connecting them, resulting in adjacencymatrices summarizing all cell-cell interactions within the dataset. Statistical significance was
then empirically assessed by permuting the receptors and ligands among all cell subsets in a degree preserving manner (using edge
swaps but only for uniquely connecting pairs), thus preserving the number of receptors and ligands encoded within each cell subset,
but changing the connectivity between cell subsets. After running 10,000 total permutations, p values were computed as the number
of times the edge strength in the permuted network was greater than or equal to the edge strength in the true network.Cell 178, 714–730.e1–e13, July 25, 2019 e11
To plot cell-cell interaction networks, we applied the Fruchterman-Reingold layout algorithm to a network defined using the –log10
transformed p values, using only the edges with p value < 0.05. Although edge weights were used to generate the layout, they were
removed from the final visualization for visual clarity.
Using receptor-ligand interactions to predict cell proportions
For each receptor-ligand pair in the cell-cell interaction network, we computed the Spearman correlation coefficient between the
mean log2(TP10K+1) ligand gene expression in the ligand-expressing cell and the logit-transformed proportions of the receptor-ex-
pressing cell across samples.
Defining IBD associations and candidate risk genes
We compiled a list of IBD, UC, and CD associations from recent large-scale IBD genome-wide association and fine-mapping studies
(de Lange et al., 2017; Huang et al., 2017; Jostins et al., 2012; Liu et al., 2015). Risk variants can act either in cis or in trans and esti-
mating the precise effect of any given variant is an active area of research that is beyond the scope of this work.We therefore opted to
map the genetic associations to all genes in their region of linkage disequilibrium (LD). After removing association signals mapping to
more than 50 variants (through fine-mapping if available, or in LD with the best-association SNP with R2 > 0.6), we arrived at 211
associations (comprising 120 associations for both UC and CD, 31 associations unique to UC, and 60 associations unique to CD)
that collectively spanned over 531 candidate risk genes (comprising 285 genes for both UC and CD, 63 genes unique to UC, and
199 genes unique to CD).
Defining putative IBD risk genes
Although the gene driving the signal of association is often unknown, in some cases, we can pinpoint a gene that is particularly likely
to be associated with disease risk. These putative risk genes were defined as genes containing a fine-mapped or nonsynonymous
protein coding variant, or which were the only genes in their region of LD (Table S6). To this set, we added SLC39A8 as an additional
IBD risk gene, which contains a fine-mapped variant associated with IBD risk (M.J.D. and R.J.X., unpublished data). In total, we iden-
tified 82 putative risk genes (comprising 48 risk genes for both UC and CD, 9 risk genes unique to UC, and 25 risk genes unique
to CD).
Construction of gene modules
To construct modules of co-regulated genes, we first used MAGIC v0.1 (van Dijk et al., 2018) to impute gene expression data in the
log2(TP10K+1) matrices for epithelial, stromal, and immune cells. MAGIC was run separately for healthy individuals and ulcerative
colitis patients. MAGIC was run with the recommended settings from its GitHub repository (including optimal t selection, ka = 4,
and all other parameters set to their default values). To construct gene modules, we calculated the Pearson correlation coefficient
between a query gene and all other genes in a cell subset using the imputed expression data. While prior studies of RNA-Seq
data have used permutation tests to estimate a null distribution of correlation coefficients to determine cutoffs for genemodulemem-
bership, this approach did not work well with MAGIC imputation, due to computational constraints. We therefore used a fixed cutoff,
retaining the top 100 genes with the largest correlation coefficients for each gene module. We constructed gene modules for all
candidate IBD risk genes, using cell subsets where the gene is expressed in at least 1% of all cells. Modules were defined as those
containing a significant excess of putative IBD risk genes (q < 0.05). To estimate q-values for a given module size, we constructed
modules from 100 datasets in which the gene labels were permuted, and modules were calculated with the same seed genes. The
false discovery rate was then empirically determined for each of themodule sizes (q = 0.05, 0.01, and 0.001 for modules with 3, 4, and
5 UC GWAS-implicated genes, respectively). Note that because modules are based on imputed expression data (van Dijk et al.,
2018), we verified that their genes were expressed in their respective cell types (Figure S7C).
Optimal set cover of IBD risk gene modules
To identify a minimal number of modules to explain the greatest number of putative IBD risk genes, we used the greedy set cover
algorithm. The algorithm is initialized with an empty set of ‘‘covered’’ IBD risk genes. At each step of the algorithm, we add the
meta-module with the largest number of ‘‘uncovered’’ IBD risk genes (i.e., genes not in the ‘‘covered’’ set) to this ‘‘covered’’ set.
Nominating IBD risk genes from candidate regions of genetic association
To determine whether scRNA-Seq data can help nominate ‘‘causal’’ genes from candidate gene sets, we first collapsed all risk var-
iants into 165 unique regions (comprising 99 regions for both UC and CD, 24 regions unique to UC, and 42 regions unique to CD),
reflecting distinct risk loci. Of these, 99 regions (comprising 57 regions for both UC and CD, 19 regions unique to UC, and 23 regions
unique to CD) had candidate gene sets containingmore than one gene, including at least one putative risk gene, which we termed the
‘‘correct’’ gene for that region. (In cases where a region contained multiple independent associations each with distinct candidate
gene sets, we selected the largest such set). For each candidate gene set, we then identified the gene with either (1) the highest
mean expression level across all cell subsets and disease states; (2) the largest DE coefficient in non-inflamed tissue; (3) the largest
DE coefficient in inflamed tissue; or (4) the largest module containing other candidate risk genes (iteratively defined; see Nominating
IBD risk genes using genemodules). We assessed the probability of selecting the ‘‘correct’’ risk gene using each of these four criteriae12 Cell 178, 714–730.e1–e13, July 25, 2019
and compared these results to a null model in which genes were randomly selected from risk regions across 1,000 trials. Missing
values were replaced with zeros and ties were broken by random sampling. To estimate statistical significance, we compared the
accuracy (defined as predicting the ‘‘correct’’ risk gene) of each method to the null distribution.
Nominating IBD risk genes using gene modules
Wedeveloped amethod that nominates risk genes based on their degree of co-regulation with other candidate genes from across all
IBD risk loci. This method uses no a priori knowledge of putative risk genes; instead, it is initialized with the full set of 531 candidate
genes defined across all disease risk loci. Our method assumes that IBD risk genes are co-regulated in genemodules within cell sub-
sets, as we observed for GWAS-implicated risk genes (Figure 7C). To measure this co-regulation, we therefore construct gene mod-
ules for each candidate gene in each of the cell subsets that express it, yielding 20,630 gene modules for the 531 candidate genes in
both healthy and diseased tissue (see Construction of gene modules).
We then iteratively score each gene based on the maximal number of other candidate genes it shares a gene module with, across
all such modules: genes belonging to the largest candidate gene modules receive the highest scores. To do so we use an iterative
procedure. Because the set of all candidate genes initially containsmany false positives, we iteratively weight each gene according to
our confidence that it is a risk gene, as follows. First, under the assumption that each risk region contains exactly one risk gene, the
weight for gene i is initialized according to the probability that it is the risk gene: wi = 1=Ni, where Ni is the size of its candidate gene
set (i.e., the number of genes in the risk region). Thus, genes from large candidate gene sets are initially assigned small weights, and
those from small candidate gene sets are initially assigned large weights. Next, we score each gene module J according to the num-
ber of candidate genes that it contains, adjusted by the weight associated with those genes: xJ =
P
j˛Jwj, for all genes j found in
module J. Each gene is then mapped to its highest scoring module and the probability for each gene i of obtaining its module score,
pi, is estimated from the empirical distribution of module scores. Finally, we update the weights associated with each gene i accord-
ing to the posterior probability that it belongs to the risk module for its risk region: wi = ð1 piÞ=
P
k˛Cið1 pkÞ where Ci is the candi-
date gene set containing gene i (i.e., the genes that are in the same LD region as gene i). These weights, which reflect our degree of
confidence that a given gene is a risk gene, are iteratively updated in this manner until they converge on a final estimate (n = 10 it-
erations was sufficient).
To relax the assumption that each candidate gene set contains exactly one risk gene, we follow the same procedure outlined above
to estimate the weights for each gene. However, rather than using these weights to nominate one risk gene per risk region, we calcu-
late the scores for all genes and use these scores to globally nominate risk genes irrespective of their genetic locus.
DATA AND CODE AVAILABILITY
The accession number for the processed data reported in this paper is Single Cell Portal: SCP259. Raw data will be available for
download from the controlled-access data repository, Broad DUOS. Code used in this study will be available at https://www.
github.com/cssmillie/ulcerative_colitis.Cell 178, 714–730.e1–e13, July 25, 2019 e13
Supplemental Figures
(legend on next page)
Figure S1. Characterization and Validation of the Discovery and Validation Cohorts of the Colon Single-Cell Atlas, Related to Figure 1
A. Cell subsets are evenly distributed across healthy individuals and UC patients in the discovery cohort. t-SNEs of major cell lineages, colored by the individuals.
B. Reproducible composition across samples. The fraction of cells (y axis) from each major lineage (color) in each lamina propria sample (x axis) in the discovery
and validation cohorts. C. Accurate classification of cell subsets in the discovery set. Confusion matrices for epithelial (left), stromal (middle), and immune (right)
cells, showing the percent of cells (dot size and color) from each cell subset in the test cohort (y axis) that are predicted to belong to each cell subset as defined in
the discovery cohort (x axis). D. Concordance of discovery and validation cohorts. t-SNEs of epithelial (left), stromal (middle), and immune (right) cells showing co-
embedded cells (STAR Methods) from both the discovery and validation cohorts, colored by cell subset assigned in each cohort. E. Reproducible single-cell
profiles from samples collected from the same individual and from different individuals. Distribution of correlation coefficients for cell proportions (top) and
expression levels (bottom) between replicate samples collected from the same individual (blue) or different individuals (red), for healthy, non-inflamed, and in-
flamed tissues (x axis). Boxplots: 25%, 50%, and 75% quantiles; error bars: standard deviation (SD). F. Example of approach to correct for ambient RNA
contamination. Mean expression level for each gene (dot) in B cells (i.e., ‘‘in-group’’ expression, y axis) and all other cells (i.e., ‘‘non-group’’ expression, x axis),
indicating genes used for the robust linear regression (black), genes classified as putative contaminants (red), select marker genes for different cell types (blue),
and other genes (gray). Dashed line: robust linear fit used to estimate putative contaminants.
(legend on next page)
Figure S2. Cell Subset-Specific Features of the Colon Single-Cell Atlas, Related to Figure 1
A-C. Cell- and lineage-specific genes in key functional classes. Mean expression across the cell subsets (rows) of genes (columns) encoding cell- and lineage-
specific (STAR Methods; Table S3) transcription factors (A), G-protein coupled receptors (B), and cytokines and cytokine receptors (C), expressed those cells in
both healthy and UC samples (left), only in healthy samples (center), or only in UC samples (right). Asterisks: genes that significantly changed their cell- or lineage-
specificity between health and disease (STAR Methods). D. Specific expression of distinct key signaling genes in sensory epithelial cell subsets. Fraction of
expressing cells (dot size) and mean expression level in expressing cells (dot color) of selected signaling genes (columns) across cell subsets (rows).
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Figure S3. Cell Composition Changes during UC Highlight Changes within Plasma B Cells and in M Cells, Related to Figure 2
A,B. Cell proportion changes. Significant changes in cell frequency (y axis), assessed within a class using a Fisher’s exact test (A) or a Mann-Whitney test (B), for
non-inflamed (light blue) and inflamed (white) samples relative to healthy samples (dark blue) (adjusted p values, * = 0.05, ** = 0.01, *** = 0.001); error bars: SEMC.
Relative increase in IgG+ and decrease in IgA+ B cells among plasmaB cells with disease. Fractions of IgA+ (x axis) and IgG+ (y axis) B cells out of all plasmaB cells
in healthy (blue), non-inflamed (green), and inflamed (red) samples. Dashed line: linear fit. D.Microfold (M)-like cells in inflamed biopsies. Representative images of
combined smFISH and IFA of M-like cells in colon TMA showing their presence in inflamed human colon (no M-like cells were observed in healthy tissue from 10
different biopsies). Yellow arrow: M-like cell, scale bar, 50 mm; Inset, x5 magnification. E. WNT2B+ and WNT5B+ fibroblast markers are expressed in distinct
subsets of IAFs. t-SNE of scRNA-Seq profiles from IAFs, colored by the mean expression of markers for WNT2B+ fibroblasts (top) or WNT5B+ fibroblasts
(bottom). IAFs that express WNT2B+ markers typically do not express WNT5B+ markers (and vice versa).
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Figure S4. Cell- and Lineage-Specific Expression Changes in Inflamed versus Non-Inflamed Tissues, Related to Figure 3
Volcano plots of genes that are differentially expressed in inflamed cells relative to non-inflamed cells, showing the effect size in inflammation (i.e., discrete DE
coefficient, x axis) and statistical significance (y axis). (A-C) General changes thatwere shared acrossmultiple cell subsets within (A) epithelial, (B) innate (including
stromal and myeloid cells), or (C) adaptive immune compartments. (D-F) Unique changes that were specific to cell subsets within these compartments. Selected
genes are highlighted, all genes are reported in Table S4.
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Figure S5. Changes in Transcriptional Programs in UC and Colorectal Cancer, Related to Figure 4
A. RSPO3+ cell profiles are enriched in signatures of poor prognosis in colorectal cancer (CRC) (Calon et al., 2015; STAR Methods). Distribution of the mean
expression (x axis) of a stromal gene signature of poor prognosis in CRC in the three highest scoring cell subsets and other compartments (y axis); crossbar:
mean. B. Inferred expansion of inflammatory fibroblasts with colorectal cancer. Left: mean expression of IAF marker genes in colorectal cancer samples (y axis)
and inflammatory fibroblasts (x axis). Black line: linear regression. Select genes annotated. Right: distribution of IAF gene signature scores in bulk RNA-Seq data
from colorectal cancer patients (blue) versus healthy controls (red) (***p < 0.001, Mann-Whitney test). Boxplots: 25%, 50%, and 75% quantiles; error bars:
standard deviation (SD, right). C. Expression changes (model coefficient, color bar) in inflamed cells relative to healthy cells for 23 KEGG pathways (rows) related
to carbon, lipid, and amino acid metabolism, and key additional pathways (apoptosis, autophagy, etc., bottom), for each cell subset (columns). Black outlines:
significant changes (q < 0.05, mixed linear model). D. Differential expression (color bar) of genes related to TNF signaling (rows) in inflamed versus healthy
samples across cell subsets (columns). Dot size: fraction of expressing cells in healthy (gray outline) or inflamed (black outline) samples; dot color: significant DE
model coefficients (q < 0.05, MAST hurdle model).
Figure S6. Cell-Cell Interactions May Explain Shifts in Cellular Proportions during UC, Related to Figure 6
A. Treatment of human colon spheroids (n = 3, 2 CD and one UC patients) with IL-22 induces the transcription of genes that are significantly enriched in
enterocytes. Distribution of mean expression (y axis) of gene signature enriched in IL-22 treated human colon spheroids across cell subsets (x axis);
P value, *** < 1010 for enterocytes versus all other cells; Wilcoxon test. B,C. LASSO based models (STAR Methods) explaining the change in cell proportions
across samples in IAFs (B) and M-like cells (C) as a function of both positive (dark gray pointed arrows) and negative (light gray blunt arrows) relations to ligands
(edge label) expressed by other cell subsets marked by lineage (color). Shown are all ligands with non-zero coefficients in the regularized LASSO model.
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Figure S7. Expression of Risk Genes across Cell Subsets Highlights Key Cell Types and Pathways in UC, Related to Figure 7
A,B. Differential expression of putative IBD risk genes in specific cell subsets. For GWAS-implicated IBD risk genes (columns) that are differentially expressed in
non-inflamed (B) or inflamed (C) cells versus healthy cells, shown is the fraction of expressing cells in healthy (gray outline) or diseased samples (black outline) in
each cell subset and significant DE model coefficients (color, q < 0.05, MAST likelihood ratio test). C. Co-expression meta-modules are expressed in their
respective cell subsets. Distribution of gene expression levels (x axis) in cell subsets (y axis) for each of the putative risk genes in the meta-modules for PRKCB in
healthymacrophages (left),C1orf106 in UC enterocyte progenitors (center), and IFIH1 in UCBEST4+ enterocytes (right); crossbar: mean. D. Co-expressionmeta-
modules can help nominate multiple risk genes across candidate gene sets. Receiver operating characteristic (ROC) curve showing the true positive rate (y axis)
and the false positive rate (x axis) for nomination methods across different cutoffs for gene expression levels (red) and meta-module scores (blue).
